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Abstract 
In recent years there has been a tremendous increase in the number of investigations 
regarding the nanoscale vesicles passed between cells in the body collectively known at 
extracellular vesicles (EVs). The present consensus within the community is that these 
nanoparticles are critical regulators of signaling between noncontacting cells. They have 
been demonstrated to carry functional cargos including nucleic acids and proteins which 
can modulate activity in recipient cells. Extracellular vesicles have been proposed as an 
ideal delivery vehicle for new therapeutic modes such as RNA interference. In spite of 
the tremendous body of research there is little agreement on what exactly constitutes an 
EV, the challenges of separating EVs for use in the clinic, and the influence of current 
isolation methods on downstream results. Herein the basic biology and numerous 
methods for isolating and detecting EVs are reviewed and discussed.  
In the context of potential therapeutic applications the recovery of EVs by a traditional 
ultracentrifugation isolation and reagent precipitation is investigated using a particle 
balance approach. The losses and variability inherent to the isolation protocols are 
quantified and compared.  The productivity of the selected HEK-293T cell line for 
producing EVs in culture is characterized and the potential obstacles to realization of EV 
therapeutics at scale are analyzed. 
Separately the fluorescence detection mode of Nanoparticle Tracking Analysis (NTA) is 
characterized to determine the number of flourophores which must be entrained in a 
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single nanoparticle for tracking. This work is needed in the field because while the 
detection of EVs by light scattering NTA is a common technique, there is little data 
regarding the sensitivity of f-NTA. Using a model system of cationic lipoplex 
nanoparticles formed with Cy3 labeled DNA the number of fluorophores incorporated in 
successfully tracked particles is measured and an estimation of the lower limit of 
sensitivity is calculated. This result will help others in the field better plan experiments 
for biomarker identification on a single EV basis.  
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Chapter 1- Remarks on previously published work. 
 
1.1 Isolation of rare cells from blood using immunomagnetic negative depletion 
 
A large portion of my work at Ohio State was primarily focused on the separation and 
analysis of rare cells from the blood of cancer patients. There are two approaches to the 
isolation of rare cells from heterogenous mixtures, positive selection and negative 
depletion. The method of positive selection attempts to capture from the broadly 
heterogeneous pool of total blood cells, only those few cells which display a desired 
surface biomarker that is indicative of the their cancer association.  In comparison 
negative depletion seeks to remove all of the “normal” blood cells, using immuno-
magnetic labeling targeting the pan-haemopoetic marker CD45 to label all of the white 
blood cells, and a flow through system to trap the magnetically labeled cells while those 
cells which are not labeled are collected for further biochemical analysis by 
immunocytochemistry, in-situ hybridization and flow cytometry. Below I present the 
publication from Methods which details this process, the authorship was split between 
myself and Dr. Yongqi Wu, wherein I composed the introduction, methods of isolation 
and discussion on CD45 clone selection.  Dr. Wu composed the methods on 
immunocytochemical staining, microscopy, and analysis [74]. Results from the 
application of this method to cancer patient blood samples regarding the variety of rare 
cells are described in the publication by Lustberg et al [73].  
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1.2 Isolation of a subset of myeloid cells in breast cancer patients 
The Ostrowski lab at Ohio State presented an opportunity for collaboration on the 
isolation of a small subset of myeloid cells in the blood that they believed harbored 
influential microRNAs based on work in animal models. I was responsible for breast 
cancer patient blood sample processing and 6 channel flow cytometry isolation of the 
CD115+/CD14lo/CD16hi population of myleiod cells whose microRNA profile is a central 
topic of Mathsyaraja et al [118].   
1.3 Isolation of CD115+/CD14lo/CD16hi myeloid cells by flow cytometry 
1.3.1 Staining Protocol 
From the total white blood cells after the red blood cell lysis procedure described in [73] 
set aside 107 cells for labeling. Aliquot 2.5 x 105 the unstained tube. For each single color 
control add 10ul OneComp Beads for antibodies, and 10ul ARC beads for viability. The 
marker panel applied is Aqua Viability Dye, CD45-PE/Cy7, CD115-PE, CD14-
APC/Cy7, and CD16-AF700. All of the markers are conjugated directly to their 
corresponding fluorophore. To label the cells add 3ul of viability dye to the cells, and 1ul 
to the viability control tube, incubate 30 minutes at room temperature under foil. Wash 
with 1ml 1x PBS, spin at 350g for 5 minutes, discard supernatant. Add 1ul of antibody 
per million cells to the sample, and .1ul to each control tube. Incubate 30 minutes at room 
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temperature under foil, wash 2x with 1ml PBS.  Spin at 350 x g for 5 minutes between 
washes, discarding the supernatant. Resuspend cells in 350ul sorting buffer for flow 
cytometry analysis.  
1.3.2 Flow cytometry analysis  
The flow cytometry gating strategy is presented given in Figure 12. The forward and side 
scatter gate 
captures the total 
leukocyte 
population. The 
CD45lo/CD115+ 
population is 
further sorted 
based on CD14 
and CD16 
expression 
yielding 2 
populations for 
RT-PCR analysis.  
The expansion of 
the CD14lo/CD16hi 
myeloid population and corresponding drop in in the “classical” CD14hi/CD16lo 
monocytes among patient samples is shown in the results and is the population 
represented as B in the top panel of Figure 12.  MicroRNA expression analysis for miR-
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Figure 12: Flow cytometry gating strategy. TOP left panel is the CD45lo/CD115+ gate.  
Through that gate populations A (CD14+/CD16lo) and B (CD14lo/CD16+) are collected.  
The bottom left panel is CD45hi/CD115+. Through that gate populations C 
(CD14+/CD16lo) and D (CD14lo/CD16+) are collected. Population B are the myeloid cells 
of interest.  
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21 and miR-29a performed by the Ostrowski lab on the isolated CD115+/CD14lo/CD16hi  
cells showed a significant correlation with metastatic tumor burden in the patient [118].  
1.4 Concluding remarks on published work and transition to new investigations 
 From this work I gained extensive practical experience with antibody labeling and 
selection, fluorescence microscopy, flow cytometry, and the detection of rare cells.  The 
critical findings of our investigations are documented in the publications mentioned.  In 
the fall of 2013 the Analytical Cytometry Shared Resource at the Comprehensive Cancer 
Center purchased an instrument for Nanoparticle Tracking Analysis, I was charged with 
learning to perform this new analysis for users of the core facility.  This new technology 
has had a distinct influence on the rising interest in the nanoparticles of the blood, 
collectively known as extracellular vesicles. As will be reported in the following chapters 
these particles of tremendous interest currently, as they are theorized to be relevant 
messengers in all multicellular systems. The field of EV research is currently growing 
and new, methods for quantifying EVs particularly on a particle count basis are only 
lightly reported. I investigate the interesting results that accompany particle balance 
calculations on a typical bulk isolation and preparatory purification method. The 
considerations of the impact of these results would have been impossible without the 
background in circulating tumor cells detailed here.   
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Chapter 2- Review of current extracellular vesicle research and motivation. 
2.1 Introduction to the biology of extracellular vesicles and potential applications 
The term extracellular vesicles (EVs) will be used this document to cover the range of 
spherical vesicular bodies produced and released by cells smaller than 1 micron. EVs can 
be broken into three major categories: apoptotic bodies, microvesicles (MVs), and 
exosomes [1].  These terms may be used at times to indicate the specific subset of EVs 
being considered. EVs compose just a subset of materials that cells are known to release, 
which also includes small molecules, salts, complexed nucleic acids and a range of other 
macromolecules, but the biological properties of EVs are of rapidly growing interest. 
Reports implicating EVs as non-contact signaling mediators between cells have 
precipitated rapid growth of publications in the field. The transformation of EVs from 
“artifacts of processing” to a whole new class of regulated, influential particles found in 
virtually all multicellular organisms has led to researchers across fields turning their 
interest toward further understanding EVs role in complex cellular systems. This growing 
interest has however been hampered by a lack of standardized techniques for such basic 
operations as sample processing, vesicle isolation and analysis methods. These issues 
have created at times confusing nomenclature for EVs as different investigators have 
named what are likely very similar vesicles whatever seems descriptive based on their 
own results or model system, leading to terms such as oncosome, dendrosome, and others 
being used in the published literature to describe EVs. This confusion led to calls in 2012 
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and 2013 for standardization of nomenclature related to the cellular mechanism by which 
the particles arise, and for clear presentation of the methods by which EVs were isolated 
for biochemical analysis [2, 3].  Efforts to meet these standards are not currently 
widespread, and as will be discussed this can make for a difficult interpretation of the 
reported results in the field. In this chapter the basic biology, constituent molecules, and 
reported function of EVs will be discussed to provide motivation and context to the 
results reported in the following chapters.  
2.2 Definition of Vesicle Type - Based on Biogenesis 
It is widely accepted that there are 
three primary pathways for vesicle 
production in cells and each of the 
pathways defines a distinct subset of 
EVs. These pathways are briefly 
described below and diagramed in 
Figure 13 [4]. Apoptotic bodies 
cover a broad range of sizes (100-
1000nm) and are released by dying 
cells by budding from the cell 
membrane. They likely form only a 
small subset of detected EVs because their parent cell pool is small compared to the 
number of healthy cells in the absence of disease. Microvesicles (MVs) also bud from the 
plasma membrane but are regarded as distinctly different in density, with sedimentation 
at 10000 x g. Their characteristic size is given as greater than 150nm and their function 
Figure 13: A represents the pathways associated with EV release 
in a healthy cell. Exosomes accumulate in MVBs which can 
ultimately lead to release from exocytic MVBs or degradation in 
lysosomes.  The microvesicles bud directly from the surface. B 
Apoptic cells release apoptotic bodies during death. Figure from 
[4]. 
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and biomarker signature is considered distinct from other vesicles.  Exosomes, the most 
commonly reported EV type, form through an endocytic pathway featuring inward 
budding of the plasma membrane to form multi-vesicular bodies (MVB) in the 
cytoplasm, the MVB then rejoins the plasma membrane releasing the exosomes into the 
intercellular space. Exosomes are commonly reported as distinctly smaller than apoptotic 
bodies or microvesicles, with size range 30-100nm, although more recent reports have 
shifted to stating 40-100 or 50-100nm. In the hundreds of “exosome” isolations I have 
measured for other groups at Ohio State I have personally never seen a size distribution 
result which cuts off at 100nm, most show a significant population of nanoparticles all 
the way to 250-300nm. 
The ability to reliably distinguish one EV type from another in samples is an area of 
current research. Ideally phenotyping by the display of surface markers in a manner 
similar to our approach to cell classification would be ideal. A variety of surface 
displayed markers are considered ubiquitous in exosomes (as opposed to microvesicles), 
such as CD63, ALIX, TSG101, CD81, CD9, among others. However one can still find 
reports challenging these assumptions, and within individual cell types some or all of 
these markers can be expressed at different levels [5].  The confirmation of marker 
display on individual vesicles is also an elusive result, let alone multiple markers to 
define a phenotype describing a specific subset within the bulk population. Because of 
the limitations in particle by particle analysis of EVs, isolated EVs are commonly 
subjected to global profiling of protein, lipid, or nucleic acid content which highlights the 
most common constituents within the mixed population.  Throughout this document 
terms such as bulk or crude EVs will refer the pool of heterogeneous EVs isolated by any 
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nonspecific method such as ultracentrifugation, density gradient sedimentation, or 
reagent precipitation. Only in cases where EVs are captured by their display of a specific 
biomarker will they be referred to as such.  A common question throughout this chapter, 
particularly in the context of disease, asks whether the nature of EVs is inherently 
pathogenic, or if misregulation leads to pathogenic activity [6].  Further understanding of 
the function and biological activity of individual EVs will likely be required to provide an 
adequate answer. 
2.3 Vesicle Composition 
To consider the isolation and analysis it is critical to have an understanding of the known 
constituents of EVs. As complex as the cells they arise from, the total EV pool is highly 
heterogeneous in lipid composition, protein content, and cargo.  Vesiclepedia is a 
manually curated online database of proteins, nucleic acids (RNA, microRNA/miRNA), 
and lipids which have been reported in EV publications. In total 35,264 proteins, 18718 
mRNA, 1772 miRNA, and 342 lipids have been identified in the 341 independent studies 
from the past several years [7].  Much like cells, the existence of distinct subsets of 
exosomes harboring biologically relevant information is virtually certain but strategies 
for identifying and isolating these subsets are needed. Most studies of exosome 
composition use measurements of bulk exosomes preparations, with little consideration 
for the EV loss inherent to the isolation procedure. There are no current reports of in 
depth characterization of constituent molecules content at the single EV level, only a few 
demonstrations of surface protein identification on individual EVs have been shown. In 
the following sections the reported content of EVs will be briefly reviewed, the 
references given are in no way exhaustive.  
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2.3.1 Known Lipid Content 
All EVs are composed of a lipid bilayer with embedded proteins.  The constituent lipids 
are known to be related to the parent cell line, but distinct from the exact structure due to 
the nature of EV biogenesis in multivesicular bodies (MVBs). The interaction of 
lysobisphosphatic acid and Alix is critical to formation of MVBs and thus is enriched in 
exosomes [8].  Phospholipid molecules are common in EVs, such as sphingolipids, 
phosphoatidylcholines, phosphataidylserines, and ceramide. Exosome formation and 
release has been hypothesized as ceramide dependent, although other factors certainly 
play a role [9, 10, 11].  The relationship between parent cell lipid content and the 
exosomes released has been deeply characterized for the cancer cell line PC-3. Llorente 
et al. found that of 250 lipids identified in the PC-3 cells, 190 were present in the 
exosomes, along with 27 which are apparently unique to the exosomes.  The exosomes 
also contained membranes of different relative composition than the parent cell and have 
a greater percentage of protein in the membrane [12]. Overall the current literature 
supports the conclusion that EV lipids are similar in biochemical makeup to the cell of 
origin, and support the array of proteins on the surface of the EV, further functions are an 
area of active investigation. 
2.3.2 Known Protein Content 
Knowledge of the predominant protein families present on the surface of EVs is required 
to determine their biological function, and exploitation of the surface displayed proteins 
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for immuno-affinity separations and analysis 
techniques like flow cytometry and 
immunoprecipitation are common. It is 
expected that EVs harbor protein machinery 
equipping them to specifically bind and fuse 
with a target cell to deliver their cargo as 
needed. There are several markers which are 
commonly used to specifically isolate or confirm the nonspecific isolation of the exosome 
fraction of EVs, CD63, CD81, and CD9.  All three are members of the highly conserved 
tetraspanin family, but their function on the surface of exosomes is not well understood.  
More recent results have called into question whether these markers are truly exosome 
specific, as they were identified on apoptotic bodies and microvesicles also by flow 
cytometry [13].  Regarding the function of exosomal proteins a review by Pant et al. 
analyzed results published to the Exocarta database for proteins identified in EV 
publications and the ten most common function associations are shown in Figure 14. The 
results show that the most exosome bound proteins are associated with protein synthesis, 
while every other function in the top ten is connected to a disease state, which indicates 
the potentially impactful biological activity of EVs [14].  Many study aims involve 
identification of disease state linked biomarker signatures EVs, thus it is important to 
recognize that reported protein content in the literature may biased toward those 
associated with disease. Nazarenko et al report the influence of surface displayed Tspan8 
on the interactions between tumor-derived exosomes and endothelial cells, underscoring 
the important role that specific proteins may play in exosome function [15]. A recent 
Figure 14: Top ten functional associations with proteins 
identified in EVs [14] 
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study by Sinha et al, used state of the art chromatography and mass spectrometry to 
investigate the proteome of four different epithelial ovarian cancer (EOC) cell lines and 
their exosomes and compared the results with a recently published NCI-60 (cell line) 
proteome. Their results added more than 2000 new proteins to the known database. Their 
findings speak to the difficulty of developing a complete EV proteome with the 
differences between source cell lines, among the four thousand proteins identified in the 
EOC exosomes, twenty five hundred were shared with NCI-60 but 342 were unique [16]. 
The connection between parent cell proteome and EV protein content is complex, with 
supposed common markers such as CD63 showing different expression levels between 
closely related cell lines [13].  To highlight the existence of particular subpopulations of 
EVs which can be identified by surface marker display and the influence of isolation 
method on proteomics resolution, Tauro et al. compared the protein profiles detected by 
tandem mass spectrometry for three different methods of isolation for exosomes from 
cancer cell line LIM1863.  Their findings show that the population of EVs isolated by 
centrifugation is heterogeneous and that proteomics results are significantly influenced by 
the method of isolation. CD9 is identified clearly identified in all isolation methods, 
however the detection of CD81, Alix, and TSG101 was significantly increased in the 
exosomes isolated by epithelial cell adhesion molecule (EpCAM) immunoaffinity 
capture. Immunoaffinity isolation also revealed the presence of several cancer related 
proteins, not detectably by nonspecific isolation even though LIM1863 is a cancer cell 
line [17]. The type of results cited thus far come from analysis of pooled EVs, and these 
methods cannot discriminate between membrane bound, internal cargo, or EV type with 
regard to individual proteins. There are efforts currently to identify specific membrane 
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bound proteins on the EV surface such that EV subtypes could be organized based on 
combinations of surface markers they display although techniques for such analysis are 
currently limited. Determining the number of EVs within a population which display a 
specific protein has been demonstrated using fluorescent nanoparticle tracking analysis 
(fNTA).  Dragovic et al. identified the placenta vesicle marker NDOG2 on their EVs 
using antibodies conjugated to quantum dots for labeling, along with a publication on the 
methods for such analysis by flow cytometry and fNTA [18, 19, 20]. Gercel-Taylor et al 
also utilized fNTA to demonstrate the display of EpCAM and CD63 on vesicles isolated 
from cancer cell line culture [21].  F-NTA is limited to interrogating one fluorophore, 
requiring inferences on overlap between two measured markers, rather than simultaneous 
identification on the same EV. Flow cytometry is used to identify and sort individual 
cells based on their display of surface markers, but for measurement of EVs most 
commercial flow cytometers require customization due to the small size and dim 
scattering properties of EVs [22].  When properly equipped and calibrated flow 
cytometry has been utilized to identify a range of surface markers and there are reports of 
novel flow cytometry methods which greatly improve the size resolution capability to 
less than 100nm [19, 23]. Antibodies conjugated to gold nanoparticles can be visualized 
using electron microscopy (EM), although this method is more confirmatory for presence 
than quantitative for the frequency of the protein because of the losses inherent in 
preparation and limitations on the number of vesicles which can be sampled.  
Immunogold EM can be a powerful tool for confirming directional orientation of 
membrane bound proteins, as Chivet et al. demonstrated using anti GFP and anti-CD63 
labeling of EVs the orientation of membrane bound CD63-GFP construct, however this 
26 
 
cannot quantify the expression frequency [24]. Cryo-EM has also been proposed for 
determining the structure of membrane bound EV proteins, which may help elucidate the 
organization of proteins on the surface of individual EVs, which can be markedly 
different from cells as already noted [25].  In summary our current in depth knowledge of 
the protein content of EVs is largely limited to global proteomics studies which indicate 
that they commonly harbor proteins related to their cell of origin and are linked to disease 
activity.  The development of novel methods identifying multiple proteins on the surface 
of single EVs will allow for true phenotyping and further understanding of the role of 
surface displayed proteins in the biological activity of EVs. 
2.3.3 Known Nucleic Acid Content 
EVs are theorized as signaling mediators in a multitude of pathways, where one cell 
releases a nucleic acid loaded EV, the cargo is active and can modulate protein 
expression in the recipient cell through the uptake of EVs from the circulation. Thus 
characterization of these nucleic acid cargoes is of critical importance to understanding 
their pathogenic or protective actions. Copied from the same analysis by Pant et al in 
Figure 15 shows the top 10 functional associations with exosomal miRNA and mRNA 
respectively, there were not enough publications available regarding DNA to produce a 
Figure 15Left: Top ten functional associations with exosomal miRNA, Right: Top ten functional associations with exosomal 
mRNA 
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similar graphic [14]. Again it is important to remember that when probing the Exocarta 
database (currently known as Vesiclepedia [7]), most investigations which publish 
information regarding particular nucleic acid signatures do so within the context of 
association with disease, so although these profiles make exosomal nucleic acid seem 
strongly pathogenic, this a function of the direction the current research has taken and it 
would seem likely there are normal functions taking place alongside these disease 
activities [6]. 
2.3.3.1 DNA  
DNA as a cargo of vesicles has received the least amount of attention. In general it 
present only at low levels and previous reports describe ssDNA and mitochondrial DNA 
(mtDNA) as the primary forms present.  The vesicles carrying the mtDNA were distinctly 
identified as exosomes by confirmation their surface display of CD63 and Alix [26]. The 
impact of this report was simply the identification of DNA in the exosome structures, 
which at the time had not been reported. There was little other literature regarding the 
DNA content of exosomes until a recent report on the dsDNA content by Thakur et al, 
but the conclusions presented are highly impactful. The results of the investigation by 
Thakur et al, indicate that not only is dsDNA in fact the primary form present in 
exosomes, but that these dsDNA represent the entire genome of the parent cells [27].  
The paradigm shifting impact of their report will likely precipitate deeper investigations 
into the DNA content of EVs, which to date has been largely unexplored. 
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2.3.3.2 mRNA 
The characterization of RNA content in isolated EVs has been a primary research goal in 
the field of EVs since their discovery. Interest in the action of RNA loaded EVs was 
greatly influenced by the 2007 work of Valadi et al, which clearly demonstrated not only 
the uptake, but the translation of mRNA cargo from EVs in non-parent cells. This work 
reported for the first time, a new model of genetic transfer between non contacting cells, 
which has continued to be a major motivation of EV investigations and stands a landmark 
publication in the field [28]. Skog et al and Al-Nedawi et al independently investigated 
the oncogenic activity of glioblastoma derived microvesicles, reporting several key 
findings in addition to confirming the work of Valadi. The most important among these 
was the detection of glioblastoma specific EGFRvIII in EVs isolated from cancer patient 
serum, but not in healthy patients, leading to speculation about the diagnostic potential of 
EV associated mRNA signatures as they relate to disease status [29, 30]. At present 
considerable efforts are being made to further our understanding of the relative 
abundance and in vivo function of extracellular mRNA. 
2.3.3.3 microRNA 
The microRNA (miR, miRNA) content of EVs has received the most research attention 
because of its potential as a breakthrough biomarker/diagnostic tool for an array of 
common diseases. Here the biological function of miRNAs will be briefly described to 
aid the understanding of the high level of interest in the role of EV related extracellular 
miRNA. MicroRNAs are small non coding RNAs which influence the translation of 
mRNA in complex regulatory networks, they act by binding to the untranslated region of 
the target mRNA with high sequence specificity. The binding pattern of the miRNA to 
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target mRNA either suppresses translation by physical blockage or leads to degradation 
of the target mRNA ultimately downregulating endpoint molecules associated with the 
target mRNA. This suppressive activity of miRNA is not always directly responsible for 
pathogenic activity, in some cases loss of miRNA expression can in turn lead to a 
decrease in suppression of pro-disease mRNA and thus an apparent up regulation of 
disease proteins [cancer upregulation 31, 32]. Over 18000 miRNAs have been identified 
since their discovery, and their seemingly ubiquitous presence in body has led to an 
explosion of research on the topic. Elucidation of the machinery involved in the 
biological function miRNAs, namely the DROSHA, DICER, and ESCRT has been 
widely published [33]. Distinct methods of gene silencing by miRNA are known, 
involving recruitment of degradative enzymes after binding of the miRNA to the mRNA 
target, or physical blockage of the translation machinery interacting with the miRNA-
mRNA complex [33]. Most of this work is however, not distinctly associated with EVs in 
the body, instead focusing of high throughput global profiling of the total miRNA content 
in a sample, to determine expression motifs which may be distinct and relatable to 
disease state. The relationship between miRNA and EVs in particular arose based on the 
current model of cell to cell communication between remote sites being mediated by 
vesicles which can deliver active miRNA to recipient cells and thus modulate their 
protein expression through these pathways. Publications regarding miRNA content of 
EVs have provide a mixed set of results, the lack of standardization of isolation 
techniques, numerous miRNA sources (biofluid vs. cell line) and various methods of 
interrogating the miRNA isolated make direct comparison of individual studies difficult.  
There is little doubt that the miRNA content of EVs constitutes an important regulatory 
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network and there are number of useful reviews of the role of EVs in this context [34, 
35]. The work of Mittlebrunn et al, clearly demonstrates the transfer of active miRNA 
signals between cells by EVs [35]. Montecalvo et al also show a route for dendritic cells 
to transfer functional miRNA to other dendritic cells, in turn directly affecting their 
surface protein display by repression of certain mRNA translation in the recipient cells 
[36].  The relationship between parent cell and EV miRNA profiles have been studied by 
Kosaka et al. with the results showing that less than 10% of the miRNA in the cell system 
is released in EVs and the miRNA profile is enriched for certain markers in the EVs 
when compared to the parent cell miRNA profile[10].  These findings regarding the 
amount of miRNA released by cells were duplicated by Turchinovich et al, with the 
additional characterization of the miRNA content of cell culture supernatant that had 
been “cleared” of EVs.  In experiments regarding the “cleared” supernatant their findings 
were surprising, in both plasma and conditioned medium the majority of the detected 
extracellular miRNA was not pelleted with the EVs, but found in the “cleared” 
supernatant complexed to the protein Argonaute2 (Ago2), a member of the RISC family. 
They suggest that this circulating miRNA in complex with Ago2 may be the remnants of 
apoptotic activity, but more importantly that the majority of detectable miRNA is not 
actually associated with EVs at all [37, 38]. While this finding is perhaps a sensible 
result, they stand in contrast to the report by Gallo et al that the extracellular miRNA is 
predominantly present in the vesicle fraction for both serum and saliva samples [39]. 
Perhaps the preparation of serum from plasma leads to the removal or degradation of the 
Ago2 associated miRNA and thus their conclusion that the miRNA is mostly associated 
with vesicles. A major factor not considered in any of the mentioned studies is the loss of 
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EV material inherent in the isolation procedure. The magnitude of loss will have a 
profound influence on the resulting comparison between the parent cell miRNA levels 
and those found in the isolated EVs. Wide fluctuations in isolation efficiency will also 
make sample to sample comparisons difficult to draw meaningful conclusions around, 
unless of course the variation in separation performance is ignored. Determination of the 
basic realities of EV associated miRNA release, and where the miRNAs of interest are 
most concentrated clearly requires further investigation. In the context of widely reported 
potential of EVs as therapeutic and diagnostic agents determination of the frequency at 
which abundant miRNAs occur at in terms of copy number per EV isolated has been 
investigated in more recent reports. The work of Akers et al with a number of cancer cell 
line derived EVs clearly shows that even the most abundant miRNAs in the isolated EVs 
occur at frequencies of less than one copy of the miRNA per thousand EVs isolated [40].  
This result is confirmed in a separate investigation by Chevillet et al, which shows that 
the average copy number of all miRNA per vesicle is roughly 1 miRNA molecule per 
100 EVs, in general agreement with the previous report. These results raise serious 
questions regarding the number of EVs which must be screened to establish solid 
connections between EV miRNA profiles and disease status, suggesting that the current 
paradigm of a deep connection between EV associated miRNA and disease pathology 
may require revision [41]. Such a revision is directly called for by Turchinovich et al., in 
a recently published perspective which leans on the work performed by Chevillet et al., 
and highlights the value of enumeration of total EVs by NTA when considering the 
frequency of miRNA cargos [42]. Despite these concerns a recent report by Manier et al 
shows the clear prognostic value of exosomal microRNA let7e in 112 patients with 
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multiple myeloma [43]. Elucidating the true relationship between EVs, their microRNA 
cargo, and biological activity is an area of active investigation. It suffices to say that 
presently there is little doubt that EVs convey messages in their nucleic acid cargoes, but 
the capacity of this pathway for global control of various functions in the body, and 
appropriate methods of relating nucleic acid content to clinically relevant patient status 
are in the earliest phases of development. 
2.5 Association with disease state and biomarker discovery 
With their presence noted in virtually all bodily fluids and simple methods of isolation 
from tissue culture, understanding the role of EVs in disease is a critical area of 
investigation. The NIH has provided funding initiatives focused on elucidating the role of 
EV cargo in numerous diseases, and here I will review current findings regarding their 
role in cancer and neurodegenerative disorders.  These two areas are the most widely 
investigated, motivated by the quest for new therapeutic targets and reliable diagnostic 
tools for the earliest detection of metastasis.  The role of EVs in neurological disorders is 
driven by their widely accepted ability to cross the blood brain barrier, and the role of 
normal vesicles in neuronal signaling. The works cited here are again, not exhaustive, but 
representative of the type of research questions being asked regarding the role of EVs in 
disease progression.  
2.5.1 Cancer 
Cancer is the most common disease target for EV investigations and some critical 
findings regarding the role of EV in cancer biology have already been reported. The 
difficulties in treating malignant and highly aggressive cancers, which maintain rapid 
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growth within the body has motivated research into novel treatments, targets for 
treatment, and basic biologic mechanisms of cancer spread. The established roles of EVs 
regarding targeted transport of materials between non contacting cells in normal tissue, 
along with their easy isolation from cell lines and biofluids has made understanding their 
role in cancer a priority. EVs is the term of choice in this context because tumor cells are 
known to release EVs in abundance, and between while both exosomes and microvesicles 
have reported functions in tumor cell proliferation, the establishment of tumors at 
remotes sites (metastasis), and extracellular signaling, their function in the literature is 
virtually identical as reviewed by [44, 45].  A recent report by Lindoso et al., implicates 
EVs produced by renal carcinoma cancer stem cells in the modulation of mesenchymal 
stem cells (MSCs) toward a pro-tumorigenic phenotype, and in turn the MSCs support 
tumor establishment and vascularization, demonstrating the hypothesized role of EVs 
released from cancer cells as factors in metastasis [46]. Jung et al. report that the pro-
metastatic activity of conditioned medium derived from adenocarcinoma BSp73 is 
ultimately driven by the action of exosomes, which in turn depends on the appropriate 
preparation of the matrix by soluble CD44v6 [47]. Luga et al., present evidence of 
exosomes impacting the migration ability of breast cancer cells [48]. These direct 
activities of EVs are not the only mode of influence in cancer progression, it is also 
reported that tumor cell derived EVs act as an immune suppressant, inhibiting the 
function of T cells and natural killer cells while increasing the number of immune 
suppressive cells in the circulation, thus increasing the likelihood of successful tumor 
establishment [49]. Biomarkers with prognostic and diagnostic potential are also a key 
research area, a recent report from Huang et al. details the prognostic significance of 
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exosomal miR-1290 and miR-375 in castration resistant prostate cancer. The levels of 
these two miRs were significantly correlated with overall survival [50]. There are 
additional reports of the prognostic and diagnostic potential of other EV microRNA 
expression patterns in melanoma, colon, lung, and prostate cancer among numerous other 
diseases [51-54].  Continued investigation of these cancer microRNA signatures should 
precipitate meaningful advances in therapy monitoring and clinical decision making, as 
changes in the miRNA expression are theoretically detectable prior to developmental of 
identifiable symptoms. As the resolution of EV separation techniques are improved to the 
point that EVs directly expelled by tumors can be captured distinctly from those of 
normal function in patient and animal tissue samples, the true influence of EVs on cancer 
initiation, maintenance and metastasis will be clarified and more importantly the 
identification of treatable EV targets may provide a new mode of therapy which disrupts 
cancer progression at the earliest stages. 
2.5.2 Neurological Disorders 
Demonstrations of EVs crossing the blood brain barrier, their detection in cerebral spinal 
fluid, and the identification of vesicle like particles passing between neurons are the key 
drivers of interest in the roll of EVs in neurological disorders. The role EV in brain 
cancers has been reported, with identification of specific miRNA and protein signatures 
in the EVs from glioblastoma having been identified in patient CSF and cell lines [40, 
29].  Other noncancerous neurological disorders such as Parkinson’s and Alzheimer’s 
disease have also received significant attention with reports implicating exosomes as 
active players in the basic biology of both diseases [55, 56].  Alpha-Synuclein 
aggregation is characteristic of disease spread in Parkinson’s and reports have identified 
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exosome meditated transfer of alpha-synuclein between neurons, and the exploitation of 
EVs for export of alpha-synuclein.  Whether the release of exosomes by neurons is 
protective of the parent cell or pathogenic to the cells which take up the exosomes is a 
subject of debate [57, 58]. A more recent report characterizes the biological activity of 
EVs derived from the sera of Parkinson’s patients, concluding that they do carry 
bioactive signals and that appropriate phenotyping of individual EVs will help reveal the 
fraction of vesicles that can be targeted for therapeutic intervention [59]. In Alzheimer’s 
disease exosomes have been reported to have a role in insulin resistance and amyloid-
beta trafficking, and are significantly lower in cellular survival factor cargoes when 
isolated from patients with Alzheimer’s disease compared to healthy controls [56, 60, 61] 
Yuyama et al., reported increasing levels of circulating amyloid-B, and found the 
addition of exosomes to provide a protective effect although the mechanism of this 
activity is not understood [60].  The debate on whether the nature of exosome activity is 
misregulated or pathogenic by nature in Alzheimer’s is noted by Joshi et al [62].  In 
summary there are a number of potential functions for EVs in neurological disorders but 
understanding their pathogenic nature requires further investigation. 
2.5.3 Interest in exosome function in other diseases 
The connection between EVs as mediators of cell-cell communication and the myriad of 
functions which are attributed to their activity in disease states make a complete review 
impossible. The publication of meaningful results derived from EV interrogation in 
completely disconnected diseases and patient populations speaks to their ubiquitous 
nature. It will suffice to say that the same research themes presented in the review of 
cancer and neurological disorders can be found in the literature for any other unrelated 
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diseases. The questions on the true function of EV activity, and whether it is inherently 
pathogenic, or if disease activity is caused by disruption of normal EV pathways remain 
open and debated. There is little doubt that a wealth of clinically relevant information and 
potential therapeutic targets exist within the pool of EVs constantly in circulation, which 
can only be understood with time and further investigation. 
2.6 Beyond Biology- Potential EV applications in pinprick diagnostics, RNAi vehicles 
and future medicines 
Most current research questions center on EVs role in signaling within biological 
systems, and far too little is currently understood to develop interventions aimed at 
interfering directly with EV mediated cellular events. However our current knowledge of 
EVs has made for a popular proposal that they make ideal drug delivery vehicles.  Their 
apparent lack of immunogenicity, combined with the cells ability to prepackage a desired 
cargo and display a targeting molecule to direct the EV to a specific site for action is 
conceptually intriguing. This idea is proposed in greater detail with consideration of 
mesenchymal stem cells (MSC) as the exosome source by Wee Yeh Yeo et al. in their 
2013 review [63]. They claim that immortalized MSCs are the most productive cell line 
for exosomes based on affinity isolation from conditioned media and CD81 ELISA to 
quantify the productivity. The exosomes released by MSCs are therapeutic in animal 
models and immunosuppressive. Activity which the authors link to the efficacy of direct 
MSC transplantation proposing that secreted vesicles are the mediators of the therapeutic 
effect [63].  The combination of an EV delivery vehicle combined with an RNA 
interference (RNAi) molecule packaged inside, whether it is microRNA, silencing RNA, 
or others is a an intriguing possibility that has not been fully explored.   The proposed 
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connections between circulating miRNA levels their association with EVs makes it 
possible in theory to interrupt what may the root cause of many disease. RNAi 
therapeutics have already been demonstrated using artificial drug delivery vehicles for 
both and up and down regulation of specific targets in cell line and animal models, but 
the global effect of RNAi treatments is not well characterized.  A single miRNA may 
have unknown effects on pathways other than the one intended, complicating their 
development as viable treatments [64-67). The most commonly cited motivation for 
therapeutic EVs is the work of Alvarez-Erveti et al. Which convincingly demonstrates the 
isolation of EVs from dendritic cells engineered to display a targeting peptide on the 
exosome surface, subsequent loading of isolated EVs with siRNA by electroporation, and 
most importantly the expected RNA silencing response in the brain tissue of mice 
injected with the loaded EVs [68].  The number of novel demonstrations with in this 
work alone is tremendous, at once showing not only the ability to cross the blood/brain 
barrier from an intravenous injection, but an effective silencing of the target mRNA, in a 
specific cell population based on the targeting moiety engineered onto the EV surface. In 
their small scale animal model study the isolation by ultracentrifugation and loading of 
RNAi molecule by electroportation is a reasonable strategy for preparing the therapeutic 
EVs, but these processing techniques do not scale well, and at the size required for a 
widely employed therapeutic the costs become prohibitive if not insurmountable. 
Investigation of cell line transfection methods which will lead to the cell producing a 
desired RNAi molecule in culture, preferentially excreting the desired molecule into the 
culture medium packaged in an EV which displays a certain targeting moiety on its 
surface have been proposed. These EVs could then be purified from the conditioned 
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medium by an affinity based method, at once screening for both the targeting molecule 
on the surface, and ideally the cargo inside. EV packaged therapeutics are one of the 
potential breakthrough treatment methods of the coming years, with potential to treat 
virtually any disease. This report and proposals from it have motivated questions 
regarding the feasibility of producing EVs in cell culture, and the specificity of 
separations at the bench scale will be addressed in the original reports contained in later 
chapters. 
In the realm of diagnostic and prognostic EV assays many investigations aim to correlate 
some measureable biomarker expression profile in an isolated EV population with patient 
disease status.  EVs are easily isolated from small volumes of biofluids, making for a far 
less invasive method than a tissue biopsy, and less costly than a CT scan, however the 
isolated EVs may represent only a small fraction of the total population, and losses 
associated the purification process are not currently well reported.   Taylor et al. have 
published investigations in both lung and ovarian cancer regarding the exosomal miRNA 
profiles, but neither study establishes conclusive results between the measured miRNA 
and patient status [21, 54]. As presented above more recent reports of meaningful links 
between EV biomarkers and cancer status are spread across a wide range of unrelated 
cancer types. Establishing meaningful relationships between the biomarker signatures 
will require a thorough understanding of method of isolation, the true distinctions 
between extracellular and EV associated nucleic acids, and large numbers of both healthy 
and sick patients to provide adequate statistical strength in the results. There is a term 
which describes these obstacles succinctly, heterogeneity, which in this context is 
exemplified by the variations in experimental design, isolation methods, and interrogation 
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techniques across different investigations. Heterogeneity can stop a promising technique 
in its tracks, to illustrate this point, we can consider circulating tumor cells as there are 
many parallels between CTC history and the current arc of EV investigations. CTCs are 
exceedingly infrequent cells in the blood stream which are theorized to be shed by tumors 
into the blood and impact themselves at remote sites in the body, leading to metastasis. 
Significant efforts have been made to understand their biogenesis, metastatic potential, 
and heterogeneity [69, 70]. Early entrants in the field of CTCs focused on utilizing 
EpCAM as an ubiquitous CTC marker (it is in fact not ubiquitous [71]), and developing 
methods of isolating EpCAM positive cells from patient samples, then labeling the 
captured cells with additional markers such as cytokeratin to confirm their oncogenic 
origin, and finally determining the total concentration of CTCs in the body. This has led 
to an FDA-cleared screening device, CellSearch, which has identified levels of CTCs/ml 
determined by this assay which are prognostic for metastatic breast, prostate, and colon 
cancer patient outcomes [72].  However the cells isolated by CellSearch represent only a 
fraction of the CTCs owing to their requirement that a cell display EpCAM in order to be 
captured. Any valuable biological data harbored in cells, among them CTCs which do not 
display EpCAM is lost.  This leads to a classic example of screening bias, and our own 
work in the field has shown that there are a variety of CTCs present in the blood beyond 
the traditional definition, and that only a subset of the total detectable population is likely 
to have significant metastatic potential. The heterogeneity of the CTCs can only be 
realized by removing the normal cells, rather than capturing the supposed cancer cells 
[73, 74]. The parallel to draw between CTCs and EVs is that in attempting to connect a 
measureable biomarker signature from EVs to a disease state in either a prognostic or 
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diagnostic manner, it is important not to lose sight of the significant heterogeneity present 
in the populations, and that our methods of identifying and isolating, let alone 
understanding the biological function of subsets of EVs are currently poorly developed. 
This motivates the following report in which we ask basic questions about the process of 
EV isolation and comment on the impact the findings have on the current modes of EV 
research. 
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Chapter 3- A review of common techniques for the isolation and detection of EVs 
3.1 Introduction 
The production of EVs by cellular systems is seemingly ubiquitous, with EVs having 
been isolated from the conditioned medium of any cell line of interest, and every bodily 
fluid. However there is still little agreement or standardization regarding the methods 
used in isolation and detection of EVs, with several completely different isolation 
methods being widely reported in the literature and a myriad of suitable methods of 
detecting isolated EVs reported in the literature [75]. The most common isolation 
methods are sequential ultracentrifugation (UC), where the EVs are pelleted by being 
subjected to increasing high speed spins with each step in the process subjecting the 
mixture of particles to increasing sedimentation force and thus removing different 
contaminants until the pellet of the final spin (>100,000 x g} is greatly enriched for EVs 
(in particular exosomes but that will be a point of discussion).  The purity of EVs can be 
increased by incorporating a density gradient for ultracentrifugation.  Isolation kit 
reagents such as Exoquik (Systems Bioscience) and Total Isolation Reagent (Invitrogen) 
are thought to tie up the water in a sample allowing collection of the less soluble 
components such as EVs in a low speed spin after mixing. Lastly affinity isolation where 
micron size beads are functionalized with antibodies against a desired EV surface 
biomarker allowing separation of those EVs which display the marker of interest. Each of 
these techniques has its own pros and cons and selection for a specific study is often 
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based on the availability of equipment, need for purity, and past experience with the same 
technique. Methods of detection for isolated EVs are also highly varied and common 
techniques include nanoparticle tracking analysis (NTA), tunable resisitive pulse sensing 
(TRPS), electron microscopy (EM), and flow cytometry among others. No single 
technique is perfectly suited to the task of EV detection, in this chapter the first principles 
of each method and representative applications will be discussed. Based on the ongoing 
development of therapeutics in EVs it is important to understand the impact of 
separations procedures on the recovery of EVs, and in turn strengthen conclusions about 
the productivity of EVs per cell in culture, and the relative frequency of biomarker 
signals within the large, heterogeneous population of crude EV preparations.   
3.2 Methods of Isolation 
There is no standard in the method of isolating EVs in peer reviewed studies, with all of 
the common methods represented in the literature. To understand the methods typically 
employed to isolate EVs I present a basic review of the techniques mentioned briefly in 
the introduction. The goal of any isolation method is to sufficiently purify the EVs from 
potential contaminants for downstream analysis, however the composition of the EV 
source material can have significant influence on the purity of isolation. The loss of EVs 
during processing in each isolation protocol is also poorly understood and often not 
reported, despite the significant impact the losses will have on the results of endpoint 
biomarker assays [76, 77]. 
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3.2.1 Ultracentrifugation and Density Gradient Sedimentation 
During ultracentrifugation samples are subjected to a period of high gravitational force 
(100,000+ x g) by rapid spinning in specially designed ultracentrifuges. This technique is 
widely applied to 
characterize a number 
of physical properties 
of polymers and 
nanoparticles, 
including molecular 
weight, partial specific 
volume, and others 
based on their 
movement through a 
suspending medium 
[78]. In the field of EVs, UC is typically applied not as a characterization tool, but as a 
separation, with sequential spins at higher speeds removing particular components of the 
sample. Thery and colleagues have published studies which address the issues involved 
with isolation and characterization of EVs, and their protocol published in 2006 for 
sequential UC is still widely used today, with minor modifications for the isolation of 
EVs from conditioned medium and biofluids. The protocol is shown in Figure 16 [79].  
The purity of EVs isolated by UC is a subject of debate, particularly from complex 
systems biofluids like blood components when using a pelleting strategy. Momen-Hevari 
et al., note that the viscosity of biofluids (serum, plasma, saliva) is a critical factor in 
Figure 16: Flowchart for the isolation of exosomes by Thery et al. Note that cell 
debris is discarded after the 10000 x g spin, this is today considered to be the 
microvesicle fraction. Image from [79] 
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efficient sedimentation of EVs, recommending a level of dilution in order to lower the 
viscosity and pellet more of the EV content [80]. EVs isolated by UC from biofluids are 
likely contaminated with HDL, LDL, and extracellular proteins not associated with EVs.  
HDL and LDL have been noted to coisolate with EVs even when a density gradient is 
used during the UC protocol. This is an important observation because lipoproteins have 
their own subset of associated miRNAs [81-83].  The soluble protein Argonaute2 (Ago2) 
is another common source of contamination as it is an important part of the miRNA 
processing machinery. Ago2 is often found in complex with miRNA in the extracellular 
space and can co-isolate with EVs in a typical UC protocol [38].  These sources of 
contamination make it difficult to distinguish which biomarkers signals can be distinctly 
attributed to EVs.  In order to more clearly separate populations of EVs, density gradient 
sedimentation (DGS) utilizes layers of suspending medium with increasing density, 
typically sucrose or iodixonal at increasing percent weight, the sample of interest is added 
on top of the layers. After ultracentrifugation for some time all of the particles in the 
sample will have moved to their isopyntic point within the density gradient, and can be 
extracted for analysis by careful collection of each fraction, and data from DGS has 
indicated that many EVs (specifically the exosomal portion) have density 1.12-1.15 g/ml, 
although many fall outside that range in the broader 1.05-1.20 g/ml [17, 84].  While EVs 
collected from density gradient preparations are often of higher purity than dead end UC, 
the recovery is markedly lower which must be taken into account when analyzing results. 
Despite the deep characterization of the performance of the UC and DGS isolation 
methods by some research groups, there remains little consensus on whether any 
particular protocol is most appropriate Cjvetkovic et al., have reported the influence of 
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rotor type, g force, and centrifugation on recovery as measured by RNA and protein 
content of the pellet, but without enumeration of the vesicles. They conclude that most 
typical protocols are insufficient or too poorly developed to capture all vesicles in a 
sample, and all of the investigated variables are of significant influence [85]. Jeppesen et 
al., report markedly different characteristic size distributions of recovered EVs and broad 
differences in apparent pelleting times when comparing isolation by UC from two 
unrelated cell lines [86]. Within the EV research community there have been formal 
positions taken on the need to establish a standard, but little headway has been made in 
the implementation of such. In surveying the literature the only distinct commonality 
between different groups in terms of UC isolation protocol was noted when the protocol 
shown in Figure 16 from Thery et al. was cited. Those who did not cite a source for the 
protocol showed no agreement on spin rates and times for each step in the process.  
The method of EV isolation we used in the work presented in the following chapters is 
primarily ultracentrifugation. The protocol employed is not extraordinary or optimized. It 
is rather intended to represent what is a “typical” method of isolation in the field and 
from there, determine the characteristic size and concentration of particles isolated at 
each step in the process to consider the inherent losses.  
3.2.2 Proprietary Reagents 
With rapidly growing interest in EVs methods for avoiding the expensive equipment and 
labor intensive techniques involved in ultracentrifugation have given rise to several 
commercial reagents for the isolation of EVs. Examples include Exoquik (Systems 
Bioscience) and Total Isolation Reagent (Invitrogen). These reagents are sold in slightly 
different formulations (although the exact composition is not revealed) for isolation of 
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EVs from conditioned media, plasma, or urine. They are thought to work on a solubility 
exclusion principle, by using polymers to tie up the water in the system they force the 
less soluble vesicles out of the water suspension, where they can be easily pelleted by a 
short low speed spin. Manufacturer provided data suggests that these reagents purify EVs 
based on the western blot detection of common EV markers such as CD63 and TSG101, 
and claim improved recovery compared to an ultracentrifugation isolation. Rekker et al 
performed a direct comparison of the miRNA profile of EVs isolated by 
ultracentrifugation compared to Exoquik precipitation, finding the results comparable but 
the Exoquik method precipitating particles other than EVs [77].  The coprecipitation of 
contaminants by these reagents make them unattractive choices for purity, but as a 
primary isolation step they may provide enhanced recovery of vesicles which can be 
subjected to more stringent purification techniques. 
3.2.3 Immunoaffinity Isolation 
Immunoaffinity isolation is the separation of a specific subset of EVs from a bulk 
population (often pre concentrated or isolated nonspecifically) based on their expression 
of certain surface displayed biomarkers. Large (>2 µm) beads are functionalized with 
antibodies against a biomarker expected to be displayed within the population, but at an 
unknown level. By incubating the beads with the heterogeneous EVs those which display 
the biomarker desired will be captured on the bead and can be easily spun down in a low 
speed centrifugation attached to the large bead, and the uncaptured EVs are discarded 
thus creating a supposedly more homogenous population in the bead associated EV pool. 
Separation of subsets of EVs is desired to reveal whether their cargo or function can be 
differentiated based on their display of the target marker. This isolation strategy has been 
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compared to ultracentrifugation and density gradient sedimentation by Tauro et al. In 
their study EVs from the colon cancer cell line LIM1643 were isolated by each method 
and then interrogated for specific protein content by tandem mass spectrometry. Not 
surprisingly immunoaffinity capture based on display of EpCAM, a widely used marker 
for cancer associated cells, led to the identification of more oncoproteins than in those 
samples which were not enriched by affinity isolation.  However the immunoaffinity 
approach isolated more EVs by total protein analysis than a DGS method, which is 
difficult to understand [17]. Mathivanan et al purified exosomes displaying the marker 
A33 for proteomic analysis, and comments on the importance of using immunoaffinity 
purified EVs to eliminate confounding signals [87]. When properly developed 
immunoaffinity isolation can enhance sensitivity to infrequent or disease related markers 
critical to the investigation. In Chapter 4 I will probe the particle balance surrounding 
immunoaffinity isolation of EVs on magnetic microbeads with surprising results.  
3.2.4 Chromatography Based Methods 
Antibody affinity isolation using microbeads on small samples is a useful analytical tool 
for isolation of specific fractions of EVs. However it cannot meet the needs of large scale 
separation applications.  However if the antibody were immobilized on a chromatography 
matrix it might be possible to separate a large number of vesicles from complex mixtures 
like conditioned media in a typical chromatography approach.  A recent report by Boing 
et al., details the application of size exclusion chromatography for the separation of EVs 
[88].  Because the throughput available with chromatography can work at much larger 
scales than the other isolation methods it presents significant opportunities in the 
purification of therapeutic EVs at scale.  
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3.3 Methods of Detection 
Perhaps the most confounding part of EV investigations is definitive determination of the 
amount of “true” material present. More distinctly that is, the amount of protein or 
nucleic acid that is truly entrained on the surface and interior of the isolated EVs is 
difficult to measure in “total” assays as it fails to screen for contaminants and provides no 
confirmation of EV association [89].  Thus accurate determination of the size distribution 
and number count of the nanoparticles present in EV isolates is a critical measurement for 
understanding their function and validating isolation protocols.  Much like the variation 
in isolation methods there are a number of options for assessing the characteristic size 
and concentration of EVs, each with their own pros and cons.  For many years the only 
useful technique for sizing EVs was electron microscopy (EM), requiring expensive 
equipment, deep user knowledge and laborious preparation techniques which can 
influence the outcome of the measurement. While still a standard for absolute sizing, EM 
as a complementary technique to biological studies it is often too demanding on time and 
resources to work as a confirmatory technique for isolation.  Traditional ensemble light 
scattering techniques such as dynamic light scattering (DLS) and laser diffraction are 
often not suitable for determination of particle size distributions (PSD) in EV 
preparations because of the innate heterogeneity in size. EV isolates typically range from 
50-350nm in diameter, and the effect of the presence of a small number of larger particles 
in measurements by DLS is clearly described by Filipe et al in comparison to 
nanoparticle tracking analysis [90].  The disparity in determined PSDs is because Raleigh 
scattering is a sixth order function of diameter, and thus small numbers of large particles 
will overwhelm the signal from many smaller particles leading to PSD results by 
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ensemble measurement techniques which are difficult to repeat and not representative of 
the true PSD. In addition to PSD measurement, quantifying the number of vesicles which 
are present in a sample is a major obstacle as nanoparticle counting techniques were not 
well developed for polydisperse samples, and approximations of EV concentration based 
on DLS results can be essentially meaningless for broad PSDs. The issues with 
determining the size and quantity of EVs in a sample were a limiting factor in the 
research interest in the field for many years.  At present several techniques have entered 
the field with the capability to analyze EVs on a particle by particle basis and will be 
discussed briefly in the following sections. For the interested reader deep comparisons 
have been reported by Van Der Pol et al, and Mass et al respectively [100,101]. 
3.3.2 Measurement of EVs by Nanoparticle Tracking Analysis 
Nanoparticle Tracking Analysis (NTA) is a method of determining the size distribution 
and concentration of nanoparticles in suspension. Using a laser shaped such that the 
illumination depth is very similar to the focal depth of a typical microscope objective 
lens, nanoparticles can be visualized as point scatterers when measured at appropriate 
concentrations. The particles in suspension move under Brownian motion and their size is 
directly related to the velocity of the Brownian motion.  By recording videos of the 
particles moving and then determining the mean squared displacement between each 
frame of the recording for each particle visible on the screen using the associated 
software. By monitoring the sample temperature in the measurement region and requiring 
user input for the viscosity, the size of each particle can be calculated from the 
relationship between diameter and mean squared displacement presented by the Stokes-
Einstein equation [91].  Thus the resulting size is equivalent to the hard sphere 
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hydrodynamic diameter for each particle, and includes the hydration shell around the 
particle. In this way NTA results should be used as an approximation of absolute size 
with a tendency to be shifted to larger sizes compared to EM distributions. The 
interrogation of each particle builds a distribution of the sizes that is more sensitive, and 
provides higher resolution than ensemble techniques like DLS, particularly in the case of 
polydisperse samples as is demonstrated clearly by Filipe et al [90].  The particle by 
particle analysis approach of NTA also makes it possible to estimate the number 
concentration of EVs in a sample, a measurement that was previously inaccessible or at 
least exceedingly difficult to determine. However NTA is typically reported to have a 
lower detection limit of 30nm for organic particles, so vesicles near the detection limit in 
the may not be realized as an absolute number count. Because the dynamic range of the 
concentration measurement is effectively 5 x 107- 2 x 109 particles/ml most samples 
require dilution to be properly measured, sometimes more than 1000 fold. The resulting 
PSD after dilution is representative of the most frequent particle sizes in the sample, but 
lacks sensitivity to less prevalent populations.  There are numerous publications which 
have assessed the measurement of EVs by NTA, studying their size, count, and stability, 
and NTA is often used as a quick characterization tool when research questions focus on 
the biology of EVs [92, 18]. With the ability to quickly analyze isolated EVs size and 
concentration using NTA, research interest in the function of these EVs has increased 
tremendously in the past ten years and led to evaluation of a number of other techniques 
for measuring the absolute size distribution and concentration of EVs. In the following 
chapters I will use the concentration measurement of EVs by NTA extensively in the 
comparative analysis of separations techniques. 
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3.3.3 Measurement of EVs by Tunable Resistive Pulse Sensing 
Tunable resistive pulse sensing is a technique which allows for determination of the size 
distribution and number concentration of nanoparticles. The particle suspension is diluted 
to an appropriate concentration and driven across a non-conducting membrane with a 
single pore of diameter slightly larger than the particles of interest. Size and count of the 
particles are detected by a measurable change in the resistivity across the pore as a single 
nanoparticle moves through.  The magnitude of the resistive pulse event is a third power 
function of particle diameter, and a fourth power function of pore diameter [93]. TRPS 
systems can be equipped with different sized nanopores to provide detection capability 
across a range of sizes. In general larger pores will prove insensitive to the smallest 
particles in a measurement, while smaller pores can be prone to blockages disrupting the 
flow of particles through the pore and requiring user intervention to continue the 
measurement [94]. Each measurement uses a standard calibration nanoparticle solution to 
establish the resistive response to particles under the particular instrument configuration 
because several variables can impact the results and must be kept constant throughout a 
measurement including the pore strain, pore rating, transmembrane voltage, and particle 
driving pressure [93].  Direct comparisons of TRPS with other techniques have been 
made, with the dependence of the results on the size of pore chosen being clearly evident 
when compared to other techniques [95]. However when properly performed TRPS 
measurements can provide comparable size and concentration reports to other EV 
analysis techniques.  
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3.3.4 Measurement of EVs by Electron Microscopy 
Electron microscopy (EM) techniques allow for detailed determination of the size and 
morphology of EVs. It was the first widely used method of confirming EV presence after 
isolation. EM studies of the sub-micron particles released by reticulocytes are often cited 
as the first reports of EVs [96]. The study of exosomes in particular by EM gave rise to 
their popular description of 30-100nm spherical vesicles which display a cup shaped 
morphology.  Advanced applications of EM are covered in [24, 25]. EM techniques 
remain the gold standard of determining the edge to edge size of nanoparticles, including 
EVs. Some of the limitations of EM techniques are the requirement of access to 
expensive equipment, laborious sample preparation with poorly understood effects, and 
time consuming hand interpretation of results. Overall the method remains the most 
absolute method of sizing, with added benefits in the hands of experienced users. 
3.3.5 Measurement of EVs by Flow Cytometry 
Although it is not traditionally a nanoscale analysis technique flow cytometry is one of 
the most commonly reported methods of analysis for EVs, particularly for platelet 
derived microparticles [97]. There are a large number of considerations that must be 
made for effective analysis of EVs using flow, in particular the wide variation in 
instrument capabilities and equipment.  Most commercial flow cytometers cannot 
visualize polystyrene particles smaller than 300nm, making EVs, which have lower 
refractive index than polystyrene beads often used for size calibration exceeding difficult 
to detect as single particles [98]. Because a typical flow cytometer relies on sufficient 
signal on the forward and side scattering detectors to determine a particle of interest has 
been measured the lack of scattering signal from vesicles leaves them lost to the 
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instrument noise. Van der Pol et al have produced detailed publications regarding the 
analysis of EVs with flow, concluding that most vesicle detection can be attributed to 
large single vesicles or what they term swarm detection, multiple smaller vesicles passing 
through the detector at the same time and triggering an event as if they were a single 
vesicle [99]. This makes enumeration of vesicles with flow cytometry exceedingly 
difficult, although the confirmation of biomarker presence by the fluorescent signal is 
still measured in a semi-quantitative result.  The widespread access to equipment and 
common knowledge of the technique make flow cytometry an oft used method of 
biomarker identification on EVs, although some reports push the technique to the limit of 
detection. 
3.3.5 Additional Methods 
There are methods of determining the size distribution and concentration of nanoparticles 
which can be used to EVs. These include asymmetric field flow fractionation, various 
chromatography techniques beyond size exclusion, and dynamic light scattering.  Their 
application is less frequently reported in the literature than the methods described above, 
although each technique can provide insightful data on the EVs of interest. A thorough 
comparison of these less often used methods has been presented in 2013 Van Der Pol et 
al, and 2014 by Petersen et al, respectively [102, 103]. 
3.4 Concluding comments on detection and isolation 
An important observation to take away from the cited literature is the variation in 
performance measurement for isolation techniques. If the scientific question asked needs 
only to confirm the presence of EVs and we screen for whether the EVs are present, the 
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answer is often yes, the EVs are present. The question that has often gone unasked is 
quantitative, what is the recovery in terms of particle number and morphology. How 
many particles of typical EV size are present in measurement, for a functional assay 
regarding the activity of EVs measured by exact amount of active “reagent” being used is 
not simple to determine. With the acceptance of EVs as signaling mediators, particularly 
in RNAi, the need for clear understanding of their prevalence within an experiment is 
critical. Questions of scalability for these types of processes must be addressed for 
realization as therapeutics. In the following chapters I will directly compare the recovery 
of particles by the kit reagent to that by ultracentrifugation and discuss the implications of 
the findings within this context using NTA detection for sizing and enumeration of the 
EVs in each sample.  
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Chapter 4- Closing the particle balance on EV isolation, determining the 
productivity of culture systems for therapeutic EV applications. 
4.1 Introduction 
Based on their demonstrated biological function, natural display of targeting molecules, 
and lack of immunogenicity EVs have been proposed as ideal drug delivery vehicles [63, 
104-107]. As natural mediators of nucleic acid signaling their development as potential 
RNA interference (RNAi) treatments is a real and current topic of investigation. Many 
publications demonstrate the variety of effects these treatments can elicit, focusing on the 
knockdown of specific protein targets in particular organs as expanded on in Chapter 2.6. 
There are obstacles which must be overcome in order to realize RNAi therapeutics. The 
large scale synthesis of therapeutic oligonucleotides, and development of a suitable 
delivery vehicle make investigations larger than laboratory scale prohibitively expensive. 
Thus strategies for programming cells to load their naturally produced EVs with a desired 
nucleic acid (which they already have the machinery to accomplish) is an ideal 
exploitation of cell culture produced therapeutics. What is often given little attention in 
the current literature is the capacity of cellular systems to produce EVs for these 
applications. Studies of the effect of EVs in cellular or animal systems typically call for 
doses on the order of µg, but it has been questioned what exactly constitutes 1 µg of 
exosomes [108].  Despite the lack of characterization to determine what molecule within 
the pool of EVs is responsible for therapeutic effects the promising results in terms of 
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efficacy demand investigations into the productivity of the cells to better define the issues 
with scale up that must be addressed.  In collaboration with Dr. Schmittgen’s group who 
are investigating exosome based RNAi treatments we conducted a study to determine the 
EV productivity in spinner flask cultures, comparing the recovery of EVs by 
ultracentrifugation and precipitation reagent (Total Isolation Reagent from Invitrogen) on 
a number count basis. By measuring the size distribution and concentration of the 
nanoparticles present at different steps in the isolation process we identify losses and can 
project the scalability of production.  The nomenclature for samples in this chapter is as 
follows, 10K refers to the supernatant drawn off after a 30 minute centrifugation of the 
conditioned media at 10000x g, which should be free of cellular debris and dense 
microvesicles. Clear refers to the supernatant after the 1.5 hour spin at 100000x g which 
should be free of virtually all particles. Extracellular vesicle pellet (EVP) refers to the 
resuspended extracellular vesicle pellet from the 100000x g spin. Throughout this chapter 
the term nanoparticles will be used to describe the concentration and size distribution 
results, this is a prudent discussion on the topic and it would be too bold to claim that 
every particle measured is actually an extracellular vesicle in light of the known 
contaminants. 
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4.2 Methods and Materials 
Isolation of EVs from HEK293 Conditioned Media 
EVs are harvested from the conditioned culture medium of 
human embryonic kidney 293 T (HEK 293T), adapated for 
growth in suspension and exosome free media. Fetal bovine 
serum (FBS) is a common supplement to culture media but is 
known to contain large numbers of bovine EVs, these are 
removed by ultracentrifugation before the media is prepared.  
Thus when evaluating the EV content of the conditioned media 
we can infer that EVs are all from the cells of interest and not 
contaminants from the media. Cells were grown in 400ml 
spinner flasks with ATCC media supplemented with 8 mM L-Glu 
and exosome depleted 2.5% FBS. Cells were passaged to fresh 
media after 72 hours of growth with confluence greater than 80%.  The conditioned 
media was subjected to the EV isolation protocol in Figure 17. Isolated EVs were either 
used immediately or stored at -80 C. We defend the ultracentrifugation protocol only as 
being representative of those used in many other studies (see Chapter 2.2.1).  The 
addition of a density gradient, or additional filtration is known to reduce the recovery of 
the isolation and was thus left out of this protocol, as the goal is to understand the 
maximum productivity of the culture system, not optimization of the separation 
technique. 
 
Figure 17: Protocol for the 
isolation of EVs from 
conditioned media of HEK-
293T 
. 
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Isolation of EVs using Invitrogen Total Isolation Reagent 
From the 10K supernatant volume, one ml was set aside for isolation with Total Isolation 
Reagent (Invitrogen).  Isolation of vesicles by reagent precipitation was conducted 
according to the manufacturer’s instructions. Briefly 1 ml of conditioned media was 
mixed with 500 ul of the reagent, pipetted vigorously, vortexed and stored at 4 C 
overnight. EVs were isolated the following day by centrifugation at 10000 x g for 3 h. 
The pellet was resuspended in 1ml PBS for measurement by NTA. 
Measurement of EVs by Nanoparticle Tracking Analysis 
The size distribution and number concentration of the EVs in each sample was measured 
using a NanoSight NS300 (Malvern Instruments) with 532nm laser source and high 
sensitivity Hamamatsu sCMOS camera.  All samples within each set (10K, Clear, EVP) 
were measured at two dilutions to verify the concentration result. The settings for camera 
level and detection threshold were held constant for all samples. Three captures of 60 
seconds were taken under syringe pump flow. Further consideration of this method of 
particle counting is given in later sections of this chapter. 
4.3 Closing the particle balance 
There are a number of approaches for considering the apparent recovery of EVs in 
isolation procedures. One often used method is tracking the total protein isolated and 
assuming the result is representative of the EV concentration in each step, although the 
correlation between EVs and total protein can be highly influenced by contamination 
[89]. A more refined approach based on protein content is measuring specific proteins 
such as MHC II, which are known to be associated with EVs [79].  Using this method 
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Lamparksi et al., probed the isolation of exosomes by classical ultracentrifugation, 
determining that 5-25% of vesicles are recovered [104]. A drawback to this method is the 
unknown level of specificity for the intact EV particles, and the requirement to develop a 
correlation between the measured protein content and EV particle count.  The variation in 
protein level between different preparations is driven by the co-isolation of other protein 
bearing complexes in a nonspecific centrifugation, along with soluble proteins when the 
spin time is long, as has been discussed previously.  Using NTA it is possible to 
enumerate the total particles present in each step of the process on a particles per 
milliliter basis. This begs the question of whether a particle balance around the EV 
isolation protocol can be closed. By determining the number of EV sized particles in each 
step of the isolation protocol it is possible to make assessments of the recovery and more 
importantly the theoretical maximum productivity of the culture system for EVs.  With 
respect to the specific application of EVs discussed in this chapter, the “theoretical 
maximum” must be reported because it is certain that not all the EVs measured after 
isolation contain the specific cargo; distinguishing those EVs which certainly hold the 
cargo of interest is currently not possible. The size distribution of isolated particles, 
which should change with each step in the ultracentrifugation procedure according to 
published literature is also clearly measured, such that comparisons between pelleted 
particles and those still in suspension can provide valuable insights into the strength of 
the separation. The results presented here explore the total nanoparticle productivity of 
the culture system and the losses owed to the isolation procedure. We explore the 
relationship between cell density (cells/volume) and apparent EV productivity, and the 
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effect of centrifugation on the size distribution and concentration of the isolated 
nanoparticles. 
4.3.1 Method of Concentration Determination by NTA 
Here we discuss more critically the measurement of concentration with NTA and develop 
an understanding of how the concentration result is determined. The values reported by 
NTA for concentration are number weighted, where the size distribution is based on the 
frequency of observation of individual particles of a particular size over the course of the 
measurement.  The sizing of each particle is subject to a statistical test for validity based 
on the length of time the particle was tracked: upon passing this test the track is “valid”. 
The size distribution based on “valid tracks” is fit to the measured total nanoparticle 
concentration, which is the average number of particles observed in a single frame of 
video, without regard for their size.  This fit leads to a size distribution where the area 
under the curve between any two sizes is equal to the total concentration of particles in 
that size range. The method also requires that the user be conscience of sources of bias in 
their measurement, and make strong qualitative assessments of the data in the image on 
screen while making NTA measurements. It is imperative for quantitative inter-sample 
comparisons based on light scattering that results be taken under the same instrument 
settings. 
4.3.2 Method of Dilution and its Influence on Concentration and Size Results 
NTA is a visual method and the size distribution determination is predicated on 
measuring the nanoparticles at an appropriate concentration where individual particles do 
not cross paths on screen with others frequently within the viewing volume, which 
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corresponds to an 
optimal total 
concentration in the 
108-109 particles per 
milliliter range. Below 
this concentration long 
(>60 sec) videos 
become necessary to 
complete the 200 valid tracks per measurement required for confidence in the size 
distribution result (the agreement between repeat measurements is also indicative of 
sufficient capture length), and above which it becomes impossible to identify all the 
particles in an image because of their density in the viewing volume. I have verified the 
linear response in concentration result for both 100nm and 56nm polystyrene standard at 
different dilutions over the working range as shown in Figure 18. It would is known that 
above the range measured the response shows a flattening of the linear trend as the 
maximum number of particles which can be tracked is reached. 
Preparations of EVs (from any source) are typically several orders of magnitude more 
concentrated than is suitable for NTA measurement thus requiring serial dilution for an 
accurate measurement of the size and concentration. For proper results from serial 
dilution it is important to maintain correct and consistent pipetting technique.  I 
personally recommend diluting no more than 100x in any one step, and avoiding very 
small volumes (<5 % of total), it is most common to dilute samples to 1ml total volume 
for analysis, using the first 600ul to prime the instrument, and taking the measurement 
Figure 18: Serial dilutions of 100nm (squares), or 57nm (triangles) monodisperse 
latex beads to verify linear response of NTA concentration measurement. 
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within the remaining 400ul. Measuring the same sample at two dilutions a factor of two 
apart, and verifying the linear response of the concentration reported is a method of 
verification for the measurement results, and the slope of the linear fit to all dilutions 
within each sample pool is given in Table 6. Table 6 shows two important results, first 
the average column indicates that the expected concentration response was observed 
between dilution levels.  Second the standard deviation of the response is near 10%, 
which is in line with the run to run standard deviation of the measurement technique. 
These two results give confidence that the nanoparticle count for each sample is accurate. 
At the upper limit of the concentration 
measurement the NTA instrument will 
report 3- 4x109 particles/ml, but at that point 
the particles are too densely packed and the 
number of tracks is at a maximum, which 
means that the concentration can be 
underrepresented. Although these upper 
values can be measured, from experience reliable results are less than 2x109 particles/ml, 
based on Figure 18, where the result is linear with dilution. As the EV density in a 
measurement increases it might be supposed that with higher concentration there will be 
an inherent tendency to report larger modal size for the distribution, as smaller particles 
are occluded by the larger particles. However plotting the results from every 
measurement used in this investigation as modal size against concentration we see that 
the measured concentration is not related to the determined modal size when particles are 
diluted appropriately, as clearly show in Figure 19.   The noted lack of association 
Table 6 Avg. Slope St Dev 
10k 1.06 .10 
Clear .97 .09 
EVP .96 .09 
Table 6: Verification of concentration 
measurement for each sample pool. A perfectly 
linear response would yield and average slope of 
1. The standard deviation of the slope calculation 
is in agreement with the typical variation within 
each measurement. 
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between determined concentration and size provides additional support that the total EV 
content has been 
accurately measured 
for every sample. If 
instead the linear fit 
showed a strong 
upward or downward 
trend in modal size 
with concentration 
changes both the size 
distribution and concentration result would be unreliable.  
To compare directly the result of two different measurements by NTA it is critical that 
the settings used for capture and analysis be the same. There are only two user adjusted 
settings which influence the result by NTA, 1) camera level, which is a representation of 
a certain gain, exposure, and intensity histogram set before capture and 2) detection 
threshold, which is the sensitivity of the processing algorithm to a potential particle 
during analysis. With the broad size distribution characteristic of EVs the best approach 
to NTA measurements are selection of settings which reveal the maximum number of 
particles.  This approach can be summarized as, camera level as high as possible (to 
reveal the smallest particles in the measurement), and detection threshold as low as 
possible (to track the dimmest particles).  When appropriately diluted EVs should be 
clearly separated on screen as they move, and not densely packed, with an sCMOS 
camera set up the EVs should typically allow for camera level 13-16 without saturation of 
Figure 19: Shows every NTA measurement reported here as the mode of the size 
distribution result against the measured concentration. The R-squared values for the 
linear fit to each data set show there is no clear association between concentration 
and particle size distribution mode. 
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many particles (indicated by false coloring of particles on the screen during 
measurement).  Careful consideration should be given by the user when viewing the live 
images of the particles during NTA measurement, examination of the areas between 
clearly defined particles for signal from additional particles which may be hidden is 
important.  For a sample of unknown concentration sufficient dilution is achieved when 
no further particles appear to be revealed by increasing the camera level. The detection 
threshold should be set as low as possible without triggering noise warnings, for well 
diluted samples recorded at appropriate camera level this is typically a value of 3-5 based 
on my experience running hundreds of samples for other researchers in the Analytical 
Cytometry Shared Resource at Ohio State. When the detection threshold is set too low 
the user will notice a jump in concentration without a shift in the size distribution. This 
effect arises from tracking of noise in the videos of the EVs, which is eliminated with a 
higher detection threshold, and does not have an effect on the measured distribution. 
Selection of an appropriate detection threshold is critical to producing quality data. 
Monitoring of the particles engaged for tracking by the software is an important 
qualitative visual cue during the course measurement that can be critical to producing 
high quality results from NTA. All samples in this chapter were measured at camera level 
14, and detection threshold 4 with syringe pump flow of the sample to increase the 
number of particles sampled per measurement. Dilution for each sample pool was kept 
constant such that an appropriate number of particles were measured for each sample, 1K 
measured at 25 and 50 times dilution, Clear measured at 2 and 5 times dilution, and EVP 
measured at 100 and 200 times dilution. The dilution level is chosen so that results from 
the measurement fall in the range of 1 x 108 to 1 x 109 particles/ml where both the 
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concentration and size distribution are reliable. From the different dilutions of each 
sample pool we can verified the concentration measure by the expected factor of two 
between each dilution result (Table 6), and also whether the mode of the size distribution 
is influenced by the measured particle concentration as illustrated in Figure 19. 
The details provided here regarding the verification of nanoparticle size and 
concentration measurements can be used as a guide for designing and implementing 
useful NTA methods. Despite frequent publications presenting NTA data on EVs there is 
little discussion of how these measurements are accomplished, or adequate representation 
of the variation between measurements of different samples. The need for standardization 
of measurement techniques in the field demands consideration be given to the settings 
used for both capture and processing with the goal always being able to accurately track 
and count every particle in the mixture for studies where quantitation of the EVs is 
required. Reporting of both instrument settings and sample preparation methods for the 
measurements taken will help to establish optimal methods of sharing results between 
laboratories. 
4.4 Results 
4.4.1 Regarding EV recovery by ultracentrifugation and precipitation reagent 
To determine the average recovery of EVs by each method nine 400 ml batches of 
conditioned media were subjected to isolation by both ultracentrifugation and 
precipitation reagent (using an aliquot of supernatant after the 10000 x g spin). The 
concentration of nanoparticles reported in the 10K samples is taken to represent the total 
possible EVs in the system. There is no doubt that some portion of the observed particles 
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can be attributed to protein aggregates or other contamination which falls into the same 
size regime as EVs, but conceptually this does not impact the message of the results in 
this chapter. Using the 10K concentration as a baseline, and the EVP concentration as the 
final recovered particles a straightforward calculation of the nanoparticle recovery can be 
made.  The results from all batches give an average recovery of 31 +/- 18 % by 
ultracentrifugation, and 80 +/- 57 % by the reagent method indicating an obvious lack of 
consistent sedimentation in both cases. Removing the lowest and highest values from 
each set of results gives 30 +/- 14% and 67+/- 27% respectively. Within the nine batches 
tested the isolation reagent had one result greater than 200% recovery, which leads to the 
sharp decrease in standard deviation when removed.  
As stated it is known that not every particle in the size range measured is an EV. This fact 
aside, the total particle balance is a sensible route to understanding the recovery of the 
process, with no complete losses of particles, and no recoveries greater than 100% for 
any of the batches measured by ultracentrifugation.  The reagent kit provided a higher 
recovery of particles for every batch, which would seem advantageous depending upon 
the goals of the experiment. In a situation where the vesicles will be interrogated in bulk 
for protein or nucleic acid content the superior recovery may be a beneficial for isolating 
more vesicles but in two batches the recovery was calculated as greater than 100%, 
indicating that the reagent adds a measureable level of particles to the isolated EVs, so 
the true improvement in isolation is difficult to quantify by particle balance alone. The 
coprecipitation of contaminating species with the reagent method is not well understood 
in the current literature and sentiment within the field weighs against the use of reagents 
as an isolation technique although the data to support such is not widely disseminated. 
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The overall low recovery by 
ultracentrifugation demands answers 
regarding the fate of the missing 
particles. If all EVs fall into the 
reported density range of 1.10-1.20 
g/ml, there is no explanation for their 
disappearance from the EVP samples. 
Measurement of the Clear supernatant remaining after the high speed spin (see Figure 17) 
from each batch found that 3-15% of the particles from the 10K were still in suspension 
after the 100,000 x g spin. The exact percentage of particles in the clear sample for each 
batch is presented in Figure 20. In order to compare the size distributions in the samples 
with different total concentrations and dilution levels, the size distribution from each 
measurement is normalized to the measured concentration to give a number fraction 
distribution. 
The average number fraction 
distribution of all samples 
from the Clear, 10K and EVP 
is compared in Figure 21, 
which shows the Clear 
samples have decreased but 
still measurable percentages of 
particles greater than 100 nm 
when compared to the 10K and EVP samples. The shift in the mode of the number 
Figure 20:  The percentage of particles measured in the Clear 
sample for each batch, based on the 10K concentration. 
Figure 21:  Overlays the average number fraction distribution of each 
sample pool. Error bars are +/- one standard deviation and are shown on 
every tenth data point. 
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fraction distribution to smaller sizes in the Clear samples is explained by the removal of 
the larger particles during the ultracentrifugation process, this action leaves the remaining 
smaller particles representing a larger fraction of the distribution. In this way Figure 21 
does not indicate that the total number of smaller particles in the Clear samples was 
greater than the 10K and EVP because the fractions are normalized to the total 
concentration in each sample.  It is curious why these particles do not pellet during the 
high speed spin.  We must attribute this observation to one of two phenomena. Either the 
nanoparticles observed in the Clear samples are less dense than typical EVs and thus not 
pelleted in the same amount of time under constant centrifugal force, or they have 
diffused away from the pellet and back into the supernatant after the centrifuge has 
stopped if the pellet is not collected in an appropriate amount of time, although this effect 
is difficult to quantify in hindsight (the liquid handling method used for resuspending the 
pellet could also influence these results).  The more critical result is that the nanoparticles 
in the Clear fraction still account for less than 15% of the missing particles.  Where 
exactly the other nanoparticles have been lost is difficult to understand. There is no shift 
toward larger particles in the EVP size distribution, making it seem unlikely that the 
ultracentrifugation method fuses multiple EVs into a single particle. Perhaps some 
fraction of the EVs are lysed due to osmotic effects of washing after the removal of the 
medium but the consistency of count in different buffers would seem to exclude such (see 
Figure 25).  
Based on the modal values of all measurements we can approximate the most 
frequent EV diameter as being near 80 nanometers. It could be suggested that the force of 
the ultracentrifugation causes fusion. As EVs are composed of lipid membranes it is easy 
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to model the fusion based on the total lipid surface area that will compose the fused 
particle and thus its diameter. Thus it is straightforward that the number of EVs required 
to make an aggregate of diameter D, is the ratio of D to the nominal EV size, squared. 
This second order function of number aggregation also brings up another point, that the 
concentration of aggregates will be significantly lower than the original particles.  
Because there is no appreciable difference in the number fraction distribution of the EVs 
before and after ultracentrifugation as shown in Figure 21, we must assume that if most 
of the missing particles have formed aggregates they are larger than 300nm.  If such is 
the case their concentration will be 1-2 orders of magnitude lower and thus difficult to 
detect after dilution of the sample. This is confirmed by comparing the percentage of 
particles between 0 and 300 nanometers from all samples in the 10K (96 +/- 3%) and 
EVP (95 +/- 6%), with no apparent increase in the number of larger particles and no shift 
in the number fraction distribution it would seem that either the fusion is infrequent, or 
impossible to detect under the measurement conditons.  
Beyond these points the fate of the missing nanoparticles degrades into pure speculation.  
Ultimately the conclusion from these measurements is that both isolation methods 
produce wide variations in particle isolation efficiency from sample to sample and results 
of biomarker assays which show less than 20% difference may be purely a function of the 
variation in isolation protocol performance. 
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4.4.2 Regarding relationship between cell density, total nanoparticle concentration and 
EV production 
Determination of the quantity of EVs produced per cell based on the final isolated EVs 
and culture density in terms of cells per milliliter of culture volume is the critical finding 
of this investigation. Knowledge of this parameter is necessary for considering the scale 
up, total cargo capacity, and separations obstacles that will be necessary for realization of 
therapeutic EVs at scale. To date little consideration has been given in the literature to 
this value, perhaps because many biological questions regarding the function of EVs 
don’t center on the number of particles present only whether EVs in a system ultimately 
promote or suppress some cellular function. As mentioned previously the calculations 
here pertaining to the productivity must make the assumption that all detected particles 
are potential cargo bearing EVs, in this way the results here can be taken as theoretical 
maximum for production in our specific cell line and culture system. For a different cell 
line or culture strategy a similar set of measurements should be made, as the EVs 
produced by different cell lines can be variable in the quantity and biomarker display. To 
calculate the EV/cell productivity we simply used either the total particles in the 10K, or 
the total particles in the EVP normalized to the number of cells in the culture at the time 
of harvest. Intuitively one might think that more cells present would lead to more EVs in 
the conditioned medium, however the results here are surprising.  
A comparison of the average productivity for the EVs/cell based on the 10K and EVP is 
shown in Figure 22, with the difference between the two representing the processing loss 
71 
 
of nanoparticles as discussed previously. There are a number of noteworthy findings 
presented in the Figure 
22.  At a glance the 
results show that all of 
the cultures produced 
EV/per cell results 
within the same order 
of magnitude and this 
does not depend on 
whether the assessment is made using the 10K result, or EVP result, a positive result 
regarding repeatability of the process and productivity of the culture system. The percent 
recovery by each isolation method (UC vs TIR) shows the recovery is clearly enhanced 
by using the reagent kit, but two of the data points indicate greater than 100% recovery, 
with no obvious reason for the enhancement based on the UC results. Looking more 
closely at the 10K measurements (green bars), we note that three of the cultures (1, 2, and 
9) exhibited markedly greater concentrations of nanoparticles per cell after the 10K spin, 
but this did not translate into greater recovery or total EVs, and in fact these three batches 
have the lowest recovery at 7%, 12% and 16% respectively. To examine this phenomena 
we show both the 10K and EVP concentration plotted against culture density in Figure 23 
where the three batches with the lowest total cells, show apparent productivities after the 
10K spin approximately a factor of four greater than any other samples, despite the fact 
that the cell density is lower. However the nanoparticle content in the EVP is more 
consistent between samples, and the three samples with high loss of particles contribute 
Figure 22: A complete depiction of the productivity and recovery of EVs in culture. 
The bars are plotted to the unitless left axis, the values are meaningful based on the 
legend. Cell density is plotted as 1000 cells/ml to fit the scale. Red and Yellow dots 
are plotted to the right axis as percentage recovery of the nanoparticles measured 
in the 10K samples, green bar. The bottom axis is the batch number.  
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to the high standard deviation in the recovery.  The fact that three of the samples showed 
such behavior is also why 
removing the highest and 
lowest values from the UC 
based recovery calculation 
had little influence on the 
result, while removing the 
major outlier in the reagent 
recovery (batch 6) reduced 
the standard deviation by 30%.  The true nature of the increased particles in the 10K 
samples is difficult to understand and should prompt further investigation into the 
dynamics of nanoparticles in culture systems. 
4.5 Discussion 
4.5.1 Implications for at scale realization of cell produced RNAi therapeutics 
The investigation by Alvarez-Erveti et al. electroporated 150ug of siRNA into 150ug of 
exosomes [68] for each 
mouse they dosed. Using a 
molecular weight of 7000 
g/mol for a 22 NT siRNA 
sequence, and an average 
exosome density of 1.15 
g/ml, this corresponds to 
approximately 200:1 ratio of 
Figure 23: EV productivity on a per cell basis plotted against the total cell 
count, the obvious increase in apparent 10K productivity among batches with 
lower cell counts did not translate into increased EV recovery. 
Figure 24: The plot shows the relationship between the number of cargo 
bearing EVs (transformed percentage) and the volume of culture required to 
produce 4g at current productivity.  
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siRNA to exosomes.  If we guess that 2 siRNA are loaded into each exosome before 
injection, and that all loaded exosomes are recovered, this corresponds to a dose of 
roughly 70 mg/kg to achieve the demonstrated gene knockdown. Increasing the estimate 
of siRNA copies loaded in each exosome only results in an increased dosage requirement.  
For a 60 kg human this would potentially require 4 g or more of the active miR assuming 
the same dose is appropriate in humans.  Of course this estimation is based on a complete 
loading of the desire siRNA into the vesicles, which may or may not be achievable by 
electroporation as has been investigated by [109].  Our current estimate of the total 
exosome production per HEK-293T cell is 1500 +/- 700 EVs/cell, based on Figure 22, 
the high variability is reflective of the variability in the isolation process.  Using the 
number of EVs produced per cell Figure 24 relates the culture volume which would be 
required to produce 4 grams at current EV productivity (one copy of desired miRNA per 
EV), as a function of the percentage of EVs which are loaded with the desired cargo. It 
will be of critical importance to develop cell lines which are either more productive in 
terms of EVs/cell or are quite efficient at producing EVs with the desired cargo. It is 
possible that at maximum cell density the EVs in the culture reach an equilibrium 
concentration, where they are being released and taken up at the same rate on average in 
the total volume, while the lower cell densities are in a regime where the cells are still 
growing and thus flooding the media with their growth signaling EVs.  This phenomena 
is the motivation for attempts to correlate overall EV counts (in serum, urine, etc.) with 
disease status, with the idea that rapidly growing tumor cells (in the case of cancer) 
would be releasing abnormally high numbers of EVs.  In the context of disease I do not 
think this parameter is likely to be a revealing measure because the tumor cells make up a 
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small fraction of body mass, and the variation in performance of the isolation method 
across many samples makes detection of subtle changes in total EV concentration 
difficult to validate. Without a continuous method of screening the cargo of individual 
EVs it becomes difficult to understand at what point in the growth the maximum number 
of EVs loaded with the cargo of interest are available for collection, making the most 
useful separation approach some type of continuous affinity isolation which would 
constantly remove the cargo filled EVs without starving the cells of their normal 
signaling EVs. This can be related to the wildly successful method of fed batch growth 
for production of other therapeutics. 
4.5.2 Ultracentrifugation does not give size specific isolation 
An additional finding worth discussion here is that despite the ultracentrifugation 
protocol being quite similar to those which were associated with isolation of 30-100nm 
exosomes, some publications would even claim it is “optimized” to pellet a specific 
fraction of EVs, nothing in the results of our investigation suggests that this protocol has 
specificity toward smaller sizes or that the isolated EVs bear the size distribution 
commonly reported in the literature as 30-100nm for exosomes. Referring again to Figure 
21, we can see that a large portion of the vesicles measured in the EVP samples even at 
100x dilution are in the 100-200nm size range.  While this result is in opposition to the 
widely reported size distribution of exosomes which should be prevalent in the EVP 
samples it is not uncommon. In the hundreds of EV samples I have measured for various 
groups at Ohio State, no matter the isolation method, I have never seen a size distribution 
that cuts off at 100nm in exosome preparations.  However this result does make physical 
sense, if a fraction of the EVs are largely more dense than the suspending medium and 
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the suspension is spun for a sufficient amount of time to move all of the particles to the 
bottom of the tube there is no reason that larger or smaller particles would be 
preferentially pelleted in the time of the spin. The influence of vesicle density is a much 
greater determining factor as shown by Ettelaie et al, in their study of tissue factor 
bearing microvesicles. Microvesicles (MVs) are often reported to pellet at 10000xg, 
however the majority of tissue factor bearing vesicles were found in low density (1.03-
1.08 g/ml) vesicles with diameter 200-350nm as measured by NTA [84].  The measured 
size is in agreement with the literature of microvesicles being generally larger bodies than 
exosomes, but the low density is difficult to reconcile with the claim of MVs pelleting at 
lower speeds, and these low density bodies would be completely missing from an 
isolation at 10000 x g [110, 111]. As more and more new investigators join the field of 
EV research we hope that clarity will be brought to the subject of exactly which particles 
are isolated by each technique. 
4.6 Conclusion 
In conclusion this chapter highlights the valuable insights the particle balance approach 
lends to repeated isolation of the complex, difficult to characterize pool of EVs. By 
tracking the particle size distribution and concentration in each step of the isolation it is 
possible to understand the loss of EVs inherent to the isolation protocol which can be 
taken into account when analyzing biomarker assay results. The isolation of vesicles by 
ultracentrifugation either method had a high variability from sample to sample but was 
within the same order of magnitude for all samples, giving confidence that these results 
are representative of the type of production and recovery that can be expected in EV 
directed culture systems.   
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Chapter 5- Bench scale particle balances 
5.1 Introduction 
Having studied the large scale particle balance in chapter 5 we will consider here the 
particle balance at the experimental scale using anti-FLAG functionalized micron size 
beads and EVs engineered to display FLAG at their surface.  The FLAG tag is a 22 
amino acid sequence which can be expressed on either the n or c terminus of a desired 
protein, the protein (or in this case EV) of interest can be purified by using an anti-FLAG 
antibody [118]. The separation of EVs displaying a specific surface marker on micron 
size beads is widely reported in the literature for collecting purified fractions from EVs 
[17, 68, 87].  The EVs on the bead can then be eluted from the bead for other assays [68] 
or analyzed in place on the bead as described by [17, 87]. The methods for these 
isolations are often quickly noted, and validation of the number of EVs captured is not 
provided.  In this chapter we will probe the specificity and capacity of micron bead 
immunoaffinity capture of EVs from a heterogeneous pool of EVs isolated by 
ultracentrifugation on a number count basis, and ask if the particle balance around this 
type of separation is meaningful. 
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5.2 Methods and Materials 
Extracellular Vesicle Isolation 
EVs used for these experiments were harvested from the conditioned media of HEK-
293T cells using the ultracentrifugation protocol described in Chapter 3. EVs from a 
modified HEK-293T line engineered to display a FLAG peptide at the surface exposed 
end of the membrane bound protein Lamp2b were created by Dhruvit Sutaria of 
Schmittgen lab.  
Preparation of functionalized beads and estimation of capture area 
2.8 um Protein G functionalized Dynabeads (Invitrogen) were prepared according to the 
manufacturer instructions with anti-FLAG (mouse IgG1).  Protein G is superior to 
Protein A for immobilization of mouse IgG1, and the stated capacity for Ab is 8ug/mg 
beads, beads are incubated in binding buffer with Antibody (Either anti-FLAG or anti-
CD45 (mouse IgG1) corresponding to 16ug/mg total in binding buffer for 15 min, 
washed with 1 ml washing buffer and resuspended to an appropriate volume in PBS for 
the experiment (dependent on the number of incubations which will be performed). 
Antibody capture on the bead was verified by flow cytometry.  
Incubation of EVs and Beads 
EVs were counted prior to each incubation experiment and stored at -80 C between 
experiments. An aliquot of 109 total EVs were used for each incubation with an 
experiment dependent aliquotof anti-FLAG functionalized Dynabeads in a 1.5 ml 
Eppendorf tube. The EV-Dynabead mixture was rotated at 750 rpm on a shaker to 
prevent the Dynabeads from settling during the incubation for 15 min. PBS was added to 
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bring the total volume to 1ml, the Dynabeads were gathered near the bottom of the tube 
and 800ul of the supernatant was carefully removed for measurement by NTA. 
Measurement of particle concentration by NTA 
To minimize the dilution and particle handling steps, supernatants were measured as 
drawn from the tube in the manner described in Chapter 3.2.2.  All measurements were 
taken at camera level 14 and processed at detection threshold 3. 3 captures of 60 seconds 
each were recorded with syringe pump flow, all size and concentration values reported 
are the mean +/- the standard error between the three captures. 
5.3 Experimental Design and Motivation 
Immunoaffinity isolation techniques are commonly used to purify EVs as has been 
discussed previously, but no measurement of the capture efficiency of this method or 
quantification of the number of EVs captured has been reported. With this investigation I 
look to probe the fraction of EVs collected on the surface of micron scale beads using 
NTA. To determine the fraction of EVs trapped on the surface of the bead, EV 
concentration measurements are taken of the suspension before incubation, and from the 
supernatant after the larger beads have been trapped on a magnet. The FLAG antibody 
was immobilized on the bead surface by interaction with Protein G.  Variables of 
influence included incubation time of the EVs with the beads, equilibrium position of 
bound FLAG in solution. Using a typical particle size distribution for EVs and the 
nominal diameter of the microbeads it is possible to estimate the surface area available 
for capture.  The Dynabead solution is provided at 30mg/ml which equates to 
approximately 5 x 108 beads/ml based on the density, the manufacturer does not provide 
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measurement of the exact count. Approximately 2000 closely packed EVs, based on size 
distribution as measured by NTA, would fit on the surface on one Dynabead, assuming a 
packing efficiency of 10-20% approximately 6 x 106 Dynabeads should be incubated with 
109 EVs to provide sufficient surface area for pulldown.  
5.4 Results 
5.4.1 Buffer Exposure Does Not Impact the EV Particle Count 
Figure 25 confirms that under short term exposure the composition of the suspending 
medium between PBS, .1% Tween-20, and 10mM EDTA did not have an impact on the 
particle count for identical 
volume aliquots of EVs 
(4ul from concentrated 
stock) diluted 200x to 1ml 
total volume in each of the 
suspensions. This 
confirms that incomplete 
buffer removal from the preparation of Dynabead will not confound the results of the 
incubation experiments, and that the buffers do not contribute particles to the 
measurement. Some suspending mediums such as sucrose and BSA solutions can 
contribute a measureable number of particles to the total count and the background 
particle level must be quantified to determine its influence on the results.  
 
Figure 25: Comparison of the nanoparticle count result for 4ul of crude EVs 
dispersed in different buffers. 5mM EDTA, .1% Tween20, and 1x PBS. The buffer 
does not have a significant influence on the number of particles realized. 
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5.4.2 Particle Balance Measurements Reveal Details of the Interaction between EVs and 
Functionalized Microbeads 
As a measurement of the performance of the separation the particle balance for 
immunoaffinity isolation in theory offers insights into the pulldown marker expression 
frequency, the percentage of vesicles isolated, and the influence of conditions on the 
capture of EVs. The number of particles captured as measured by the decrease in particle 
count in the supernatant after incubation is ideally indicative of the number of vesicles 
which display the FLAG tag on their surface. This measurement is beneficial because 
although the FLAG display in isolated EVs is confirmed by western blot, there is no 
information on the frequency of FLAG display within in the population.  It should be 
noted that there is little data on the frequency of any other marker reported in the 
literature either. Where we seek to 
exploit the FLAG displaying EVs as 
potentially therapeutic cargo bearing 
a particle balance using the FLAG+ 
DynaBeads  and FLAG- Dynabeads 
(CD45 functionalized) revealed 
apparent capture for all incubations, 
but with little apparent specificity for 
the antibody utilized for capture as shown in Figure 26. Note that within the error of 
repeated incubations the FLAG- Dynabeads capture an approximately equal percentage 
of EVs 38 +/- 14%, and 52 +/- 4% respectively, paired T-Test p-value = .28 indicating 
these results are not significantly different. Figure 26 is representative of results across 
Figure 26: Captured nanoparticle count on FLAG+ and FLAG- 
functionalized Dynabeads as compared to the total incubated. The 
comparable count of captured particles indicates the isolation is 
not specific for FLAG presence on the EV surface. 
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various binding buffer conditions and incubation times (short and long), in all cases the 
isolated fraction of EVs was nonspecific with respect to the functionalization of the 
Dynabead. Considering the approximation of the bead count as solid spheres of specific 
density, the calculation of the count of the beads may be grossly misrepresented by this 
method, the bead manufacturer 
does not directly state the count 
but in phone conversations 
estimated it to be closer to 2 x 
109 Dynabeads/ml, nearly an 
order of magnitude higher than 
estimated. To that point 
incubations were prepared such 
that the total Dynabead surface 
area would be one order magnitude greater than required for close packing.  Perhaps the 
extraordinary amount of free bead surface area in the mixture resulting in the nonspecific 
activity.  To investigate this I incubated the same amount of EVs (109 total particles) with 
four different levels of FLAG+ and FLAG- Dynabeads such that the concentration of 
Dynabeads was reduced an order of magnitude between the highest and lowest levels. 
The capture results are shown in Figure 27. Note that the FLAG+/- 10 loading levels are 
equivalent to the level used in Figure 26, and show a similar profile of nonspecificity. 
Reduction of the Dynabead concentration eliminates the  
nonspecific capture in the FLAG- trials, while the lowest concentration levels,  
Figure 27: Titration of Dynabead concentration with constant EV count for 
isolation of FLAG bearing EVs. The counts are the supernatant or 
uncaptured EVs, thus FLAG- values equal to the EV only (far left) are 
indicative of no nonspecific binding. The decreasing ratio of Dynabeads to 
EVs eliminates the nonspecific binding. 
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corresponding to the intended total Dynabead surface area of previous incubation show 
that 35% of the EVs are captured.  (FLAG+3, FLAG+1).  The argument for specificity of 
exosome isolation is strengthened by comparing the reduction in particle count in 
fractions of the 
EV size 
distribution 
representing 
exosomes (50-
100nm) Table 7.  Continued random nonspecific capture is noted for larger vesicles. 
The reduction in specific size ranges is well represented graphically in Figure 28.  The 
results indicate that among all variables the specific isolation of FLAG bearing EVs is 
critically sensitive to the relative concentration of the functionalized Dynabeads 
compared to the total EVs in the suspension. Under appropriate conditions the FLAG+ 
EVs can be isolated distinctly from a heterogeneous pool of EVs.  The results indicate 
that approximately 
35% of the EVs 
appear to display 
FLAG.  If the FLAG 
is also confirmatory 
for the desired cargo 
(not evaluated in 
these experiments), 
this result is 
 Table 7: Percent Reduction in Fractions of EV Size Distribution 
 Flag +3 Flag +1 Flag -3 Flag -1 P value 
50-100nm 34% 36% 1% 3% 0.0007 
100-250nm 28% 2% -11% 18% 0.74 
Mode (nm) 87 105 93 90  
Figure 28: The size distribution of the supernatant after incubation, the area under the 
curve between any two sizes is representative of the particle concentration. We not the 
decrease in the 50-100nm for FLAG+ incubations. 
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promising based on Figure 24, as greater than 20% transformation of EVs puts the culture 
volume into the region of diminishing returns for EV loading, and other methods of 
productivity increase will need to be investigated. 
5.5 Discussion and Implications 
It seems difficult to understand why there is a seemingly consistent capture of particles 
when the EVs are exposed to the microbeads, but confounding that this shows very little 
specificity to give confidence that the capture is mediated by the antibody on the bead 
surface and not some other mechanism. The control system using  Dynabeads 
functionalized with a CD45 antibody, a pan-haemopoetic marker which is not displayed 
on the HEK-293T derived EVs  indicate that a measurable percentage of the particles 
have been captured in virtually all measurements regardless of marker display. Zeta 
potential measurements of both the EVs and functionalized microbeads exclude the 
possibility of electrostatic attraction (-7mV and -35mV respectively).  A deeper reading 
of the reported results by Tauro et al, and Alvarez-Erveti raise further questions. From 
Tauro, anti-EpCAM functionalized microsphere isolation of EVs from a 500ul crude 
preparation yields 195ug of protein, yet the same 500ul of crude preparation  spun 
through a density gradient only yields 150ug of total protein in the “exosomal” fraction, 
how this is possible is difficult to understand. The interaction of EVs and microbeads is 
quite sensitive to their surface area ratios as shown in the results here, under appropriate 
conditions the particle balance method is indicative of specific pulldown, but even five 
fold changes in the bead concentration result in a complete disappearance of specificity. 
Confirmatory testing becomes difficult without specificity in the isolation, Alvarez-Erveti 
screen for Lampb1 (a common EV marker) to confirm the FLAG mediated capture on 
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anti-FLAG microbeads. However this method of confirmation would have returned a 
positive result for EV isolation in every isolation presented here as all tests apparently 
trapped EVs on the Dynabeads.  By asking the question of how many EVs are trapped on 
the bead and comparing to a nonspecific isolation we realize that the subtleties of the 
isolation are not lost to the screening technique. The more important consideration in the 
context of therapeutics is for purification of loaded vesicles which display an affinity tag 
such as FLAG.  In the event that the display of the affinity marker is also confirmatory of 
the intended cargo in the EV (which is an entirely separate and exceedingly difficult cell 
engineering investigation), the purification strategy must maximize the capture of all 
cargo bearing EVs, while minimizing nonspecific capture.  
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Chapter 6: A method of determining the limit of sensitivity for fluorescence-NTA. 
6.1 Introduction and Motivation 
NTA is an established research technique for determining the size and quantity of 
nanoparticles in suspension, as has been extensively reviewed by Matthew Wright and 
Dr. Robert Carr [112]. The vast majority of publications use the light scattering 
properties of the nanoparticles to perform NTA (scNTA). However the same NTA 
measurements can be made using nanoparticles which fluoresce under the wavelength of 
the illumination source (fNTA). scNTA measurements provide the scattering intensity of 
each particle normalized to the brightest particle observed. Because the particles are free 
to move in suspension their position in the focal plane has a large influence on the 
apparent intensity, precluding absolute measurement. Thus nanoparticles of different 
composition cannot be distinguished by their scattering intensity except for contrived 
cases where the refractive index is quite different such as metal colloids mixed polymer 
beads.  However the same NTA measurements can be performed by inserting a long pass 
or band pass filter in the optical path of the instrument at a wavelength greater than 
illumination sources and tracking the particles using their fluorescent properties. Particles 
which are fluorescent can be identified within heterogeneous populations and analysis of 
their size distribution.  With growing interest in biological entities fNTA becomes an 
option for identification of distinct subsets of EVs in the same vein as flow cytometry is 
applied for sorting cells. The fNTA technique suffers from a lack of protocols for 
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thorough labeling of infrequently displayed biomarkers, and also from the lack of 
quantification present in more common biological techniques. A western blot positive for 
CD63 is simply that, positive that some CD63 protein was present in the sample, 
providing no indication of the frequency or density of the marker on EVs without more 
detailed quantification. There are only a few demonstrations of exploitation of the 
fluorescence-NTA (fNTA) method to identify specific surface biomarkers on EVs. 
Dragovic et al showed very clearly the presence of the placental marker NDOG-2 on 
placental EVs using quantum dot conjugated secondary antibodies, and careful separation 
of the labeled particles from the free quantum dots before analysis by size exclusion 
chromatography [18, 19]. In a similar strategy Gercel-Taylor et al showed the presence of 
both EpCAM and CD63 on EVs [21]. Nikitin et al investigated the labeling of spherical 
particles featuring tetraepitope complexes from the tobacco mosaic virus with both gold, 
and fluorescent antibodies, drawing important conclusions regarding the aggregation 
state, labeling efficiency and biological activity of their particles [113]. These examples 
raise interesting possibilities for f-NTA applications, however other literature regarding f-
NTA experimentation is currently quite limited and its capabilities are not well 
characterized with regard to sensistivity. The lack of protocols for labeling nanoparticles, 
a challenge which presents substantially different challenges than labeling cells often 
complicates efforts. The potential of f-NTA to identify disease associated biomarkers on 
the surface and in the cargo of EVs demands a more careful description of its 
characteristic performance and expected limitations in order understand the proper 
interpretation of the measurements. The most pressing fundamental question regarding f-
NTA is simply, what is the limit of sensitivity in terms of fluorescent molecules which 
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must be attached to a particle for accurate tracking, and by extension when a distribution 
of nanoparticles is unevenly loaded with a fluorophore will bias in the size distribution 
and number count results develop when comparing fNTA to scNTA measurements for 
the same particles. A reliable determination of the sensitivity for a single fluorophore 
would prove invaluable for the design of experiments and interpretation of results by 
other researchers. To estimate the number of probes which must be bound to single 
particle for fNTA measurement we employ the well characterized self-assembling 
cationic lipoplex nanoparticle (CLN). By controlling the amount of Cy3 labeled DNA 
available in the reaction mixture from 100%-1% CLNs can be formed with variable 
levels of Cy3 incorporated in their structure and the careful measurement of these 
particles formed at different loadings yields insightful results regarding the lower limit 
and influence of uneven loading. The work detailed in this chapter will be submitted to 
Nanomedicine, Scott Baldwin performed the experiments, Dr. Michael Paulaitis 
developed the model, Clayton Deighan analyzed the model, discussion of practical 
applications. 
6.2 CLNs and fluorophore incorporation 
CLNs are well understood multilamellar structures which self-organize under proper 
mixing conditions when cationic lipids are mixed with DNA. The negative charge of 
DNA against the positive charged lipid bilayer leads to multilamellar structure where 
each layer is comprised of either DNA or lipids. CLNs are known to form under a variety 
of conditions with the ratio of charge between the nucleic acid and lipids present being of 
critical importance, outside a narrow range of charge ratios the lipoplex will simply not 
form at all. The type of nucleic acid used to form the CLNs is not a critical factor, with 
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reports demonstrating the characteristic multilamellar structure with plasmids, dsDNA, 
and ssDNA of varying lengths [114-116]. In this chapter will we will use short 22 
nucleotide ssDNA 
(ODN) and the same 
ssDNA conjugated to a 
single Cy3 (Cy3-
ODN) at varying 
molar ratios to form 
CLNs. The mechanism of CLN formation is currently theorized as proceeding by a 
sequential layering mechanism, wherein an initial lipid nanoparticle forms with no DNA 
incorporated, with highly positive surface charge due to the cationic polymers, a layer of 
DNA (negative charge) coats the surface of the lipid particle recruiting another nearby 
lipid nanoparticle which lyses and wraps itself around the already DNA coated inner lipid 
particle.   This layering proceeds for some time depending on the charge ratio in the 
formulation.  Figure 29 gives a visual representation of this process.  The CLNs make a 
useful particle for studying the properties of fluorescent loading because the number of 
Cy3-ODN molecules in the system is easily controlled during the formation and a model 
of their incorporation can be developed based on the measured particle size, interlayer 
spacing, and total ODN incorporation.  
Figure 29: Basic diagram of the theoretical process of multilamellar spherical lipoplex 
formation [114].  The DNA accumulates on the membrane of liposome, recruiting 
another side by side which lyses and refolds around the DNA layer, this process 
continues for some time depending on the formulation.  
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6.3 Results  
CLNs measured by 
scNTA and fNTA 
give unimodal 
distributions. We 
used a cutoff of D 
less than or equal to 
300nm for the upper 
size limit, which 
accounts for more than 99% of the nanoparticles by number. The scattering distribution is 
shifted slightly to larger sizes. We posit the reason for this difference is intensity 
variation with particle size. In Rayleigh scattering the intensity varies as a sixth power 
function of diameter, whereas the fluorescent intensity will vary with the number of Cy3-
ODNs incorporated, thus some third power function of diameter related to the particle 
volume.  This 
scattering 
relationship 
increases the 
likelihood of larger 
particles occluding 
smaller ones from 
measurement in the 
light scattering mode.  This effect can be mitigated by lowering the total nanoparticle 
Figure 30: Total Particle Size Distributions as determined by fNTA (blue), and scNTA 
(orange, note the shift in scNTA measures to slightly larger sizes. 
Figure 31: Model fit result using a characteristic fNTA size distribution in 10nm bins and 
a value of n*Cy3=100. 
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concentration in a measurement but not eliminated entirely, and as shown above in Figure 
31 the difference between fluorescence and scattering concentration measurements also 
depends on the fluorescent dye loading.   The scNTA distribution depicted in Figure 30 is 
not impacted by the loading level. Under scatter glare patterns from larger particles lead 
to noise by creating areas in the image of similar intensity to a scattering particle, which 
then rapidly disappear and reappear giving frequent short incomplete particle tracks 
which can trigger high noise warnings and in turn occlude small particles from accurate 
tracking.  Cryo-TEM images of the CLNs showed a characteristic multilamellar structure, 
confirming CLN formation.  
In order to determine the threshold 
sensitivity we must show that the 
ODNs are randomly distributed 
without regard for the presence of 
Cy3. To determine such we employ 
two types of CLN preparations. 
Loadings describe those CLNS 
which are formed with varying 
molar ratios of ODN and Cy3-ODN mixed before the CLN formation is prepared.  These 
will be compared to dilutions, mixtures of two preparations of CLNs formed with only 
ODN or Cy3-ODN respectively. The dilutions should show linear response in the 
concentration ratio ([fNTA]/[scNTA]) curve with increasing percentage of Cy3-ODN, 
this is confirmed in Figure 32. Figure 31 shows the results from the loadings, a sigmoidal 
curve bounded by 0 on the lower end and 1 on the upper end with loading preparations at 
Figure 32: Dilutions for three different loading levels. 10% 
(triangles), 40% (squares), and 100% (circles). The linear behavior 
of the concentration result differentiates the phenomena of 
dilution from that of formation under different loading of Cy3-
ODN [120].  
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greater than 60 mol percent Cy3-ODN resulting in [fNTA]/[scNTA] ratios near 1, 
indicating that at 60% loading virtually every particle contains a sufficient number of 
Cy3 molecules to be accurately tracked.  Below 60% loading the [fNTA]/[scNTA] 
decreases because not every particle formed carries sufficient Cy3 to be tracked by 
fNTA, the effect of decreasing Cy3-ODN loading percentage is pronounced in the 
loadings from 10-60% dropping the [fNTA]/[scNTA] from 1 at 60% to .21 at 10%. For 
Cy3-ODN loadings less than 10% [fNTA]/[scNTA] values continue to decrease and , 
corresponding to 0% loading and thus a [fNTA] result of 0. The sigmoidal response to 
Cy3-ODN loading percentage indicates that the ODNs are randomly distributed, if they 
were distributed based on the presence of Cy3 the response would be linear instead. The 
concentration ratio near 1 for high loadings confirms that all particles observed under 
scatter contain ODN. More critically the sigmoidal curve can be modeled to determine 
the number of Cy3-ODN which need to be incorporated into a CLN to provide sufficient 
signal for tracking, n*Cy3. The fit of the model results in a n*Cy3 value of 100, meaning 
that a minmum of 100 Cy3 molecules need to be enclosed in a particle for sufficient 
intensity to be tracked by fNTA, the necessity that the particle be visible for enough 
frames to complete the tracking is built in. The model incorporates the size distribution of 
CLNs (in 10nm bins, for reasons discussed in detail below), a hypergeometric 
distribution regarding the formation of the particles without replacement of Cy3-ODN in 
solution determines the probability that any individual particle of diameter D will harbor 
n*Cy3 Cy3-ODN or greater within each loading preparation. The total particles containing 
n*Cy3 for each loading divided by the [scNTA] is fit to the [fNTA]/[scNTA] data. The 
total available ODN molecules, Cy3-ODN (N*ODN) and ODN (NODN), available for 
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formation at each D are used to determine the probability a Cy3-ODN will be 
incorporated at any site in a 
CLN of diameter D. Using 
the 10nm binned data we 
can model each bin as 
adding a layer of surface 
area for the ODN to 
occupy, we then set a 
packing factor (nm2/ODN) 
such that the mass balance around the total ODN in the system is closed.  When 
observing the fit of the model it is important to differentiate between the experimentally 
observed values and the estimates of the model, the model will never allow for a particle 
which is set to contain less than nODN at size D to contain more than expected, this 
assumption may bias to the model to larger particle sizes in the distribution particularly 
when looking at ratios of size between fNTA and scNTA. In order to run the model we 
employ a characteristic number fraction distribution for the loaded CLNs based on the 
average of the observed distributions at 100% loading for both fNTA and scNTA shown 
in Figure 30. This helps the model fit the trend of the data rather than fluctuating with 
exactly the observed size distribution at each fluorescent loading level. We can test the 
value of n*Cy3 determined by the fit to [fNTA]/[scNTA] by looking at the ratio of 
probabilistic average size in each loading also, as shown in Figure 33.   We note that over 
all of the loadings down to 10% the ratios of ratio of average size between scatter and 
fluorescent is less than 1, that is, the mean of the size distribution in the scatter 
Figure 33: Model fit to the ratio of fNTA average diameter Dfl (nm) to scNTA 
average diameter Dsc (nm). The value for n*Cy3=35, approximately a factor of 3 
decrease from the [fNTA]/[scNTA] result. Data at loadings greater than 40% not 
shown. 
93 
 
measurement was greater, up until the 10% loading.  The consistent ratio of the averages 
between modes up until 10% loading justifies the use of a characteristic distribution for 
determination of n*Cy3 because the particles should form to the same size distribution 
during each loading preparation as the charge ratio of DNA to cationic lipid is constant. 
The upturn in ratio is driven by both the NTA measurement method and the effect of 
photobleaching of smaller CLNs loading with size. To validate its size a particle must be 
tracked by the software for a certain number of consecutive frames based on the 
calculated size, with large particles requiring more frames to validate. As the loading 
percentage decreases the total number of particles with much more than n*Cy3 
incorporated decreases, and the particles which become susceptible to photobleaching 
first are the smaller CLNs as they are more likely to have nCy3 very near n*Cy3 as they can 
accommodate far less Cy3-ODN.  This accommodation factor can be understood by 
considering the increase in ODN accessible volume with each layer added to a CLN, 
from one to five layers each additional layer increases the ODN content by 20%, and at 
15 layers approximately the maximum observed size, the outer layer accounts for 10% of 
the ODN content.  The effect of photobleaching in the low level loadings is of greater 
influence on the mean size than mode because the larger particles, which will spend more 
time in the measurement before bleaching will show a corresponding increase in 
concentration in the determined size distribution, while the small particles are under 
represented dragging the mean size away from the mean size of the characteristic 
distribution.  The disagreement in n*Cy3 between the two fits, being 100 by the 
[fNTA]/[scNTA] fit and approximately factor of three lower at 35 in the mean size fit 
may be driven by fitting the data to the least reliable points in the mean sizes data (lowest 
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loadings), or the inherent bias to larger sizes.  It is safest to label n*Cy3 as roughly equal 
to 100 molecules and characterize this result an upper approximation which may serve as 
a guide to how many fluorophores one needs to load in a single particle to accurately 
track by fNTA. In the following sections we will consider in greater depth the model 
itself, and the practical application of these results. 
6.4 Modeling Fluorophore Inclusion in a CLN 
In order to effectively model the concentration ratio [fNTA]/[scNTA] for each loading 
we must develop a model regarding the likelihood that at least n*Cy3 Cy3-ODNs will be 
incorporated in a single CLN during the formation.  The results of NTA provide a 
tremendously useful data set for this solution, as the size distribution is number weighted 
by relative concentration directly from the measurement. This number weighted 
distribution is not accessible by orthogonal sizing techniques,  for comparison the 
transformation of the intensity weighted distribution in dynamic light scattering to a 
number count weight is fraught with error.  The power in the number weighted 
distribution is it allows for accurate modeling of geometric implications of Cy3-ODN 
loading for particles of different sizes, where the volume fraction of all particles size D 
and thus the relative amount of Cy3-ODN incorporated is easily calculated. The 
discussion and calculations which follow are based upon the mathematical description for 
fNTA developed by Dr. Michael Paulaitis in Appendix B.  
Let there be a true size distribution for the CLNs independent of measurement method, 
π(D), where D is the diameter of the CLN and π (D) the associated probability of finding 
a particle at size D. Because we know from Figure 31 and Figure 33 that a size dependent 
fNTA bias occurs with decreasing Cy3-ODN loading we can use the average size 
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distribution of the 100% loaded fNTA measurement to as a characteristic size distribution 
π (D), shown in Figure 30.  From the characteristic size distribution, total nanoparticle 
concentration (Np,tot), and known total molecules of ODN (NODN) and Cy3-ODN (N*ODN) 
the fraction of all ODN available for formation of particles of each size is estimated. 
Understanding the total ODN (nODN) in a single particle represents the number of “trials” 
for incorporation of a Cy3-ODN, and we want to predict the total number of CLNs 
incorporating n*Cy3 or greater as the value of N*ODN decreases.   
6.4.1 A mass balance on the total ODN 
The value of nODN is proportional to the volume of the particle, which is straightforward 
from the multilamellar geometry. Using high resolution Cryo-TEM data we can probe the 
total volume accessible to the ODN in solution, and thus the loading level based on a 
packing factor as shown in Appendix B.  In light of the physical situation (multilamellar 
CLNs) the value of nODN can alternatively be approximated based on the number of layers 
in the nanoparticle, the specific surface area associated with each layer, and a simple 
effective packing area of each ODN (nm2/ODN), as has been done in the following 
calculations.  The effective packing area of ODN is determined such that a mass balance 
is closed on each particle synthesis around the total ODN in the system. In the 1nm 
binned data the same approach is taken but we use a volume packing factor, surprisingly 
the volume packing factor is virtually the same as the This makes the value of ODN 
incorporation efficiency (and thus the true value of NODN) a critical parameter, as the true 
value of n*Cy3 is linearly related. As an upper limit approximation the value of n*Cy3 
reported here is for the case of all ODNs being in lipoplex after formation, if it is realized 
that say 50% of the ODNs are left out of lipoplex the value of n*Cy3 will respond linearly 
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[118]. The results between either method of calculation for the value of nODN per particle 
are agreeable showing less than 10% difference for particles greater than 50nm.  
6.4.2 Binomial or Hypergeometric Distribution? 
When modeling the uptake of Cy3-ODN into a single particle it is at first simple to think 
of a binomial distribution wherein the probability of a “success” or selection of a Cy3-
ODN can be calculated 
as the mol fraction of 
Cy3-ODN in the 
formulation.  This 
assumption may not hold 
in the region below 10% 
loading, where the 
frequency of Cy3-ODN is greatly decreased and a hypergeometric model, which accounts 
for trials “without replacement” may be more appropriate. Appendix B calls for the 
cumulative hypergeometric distribution that a particle containing nODN, will contain more 
than n*Cy3  when formed in 
a mixture containing NODN 
and N*ODN based on the 
total particle volume 
fraction associated with the 
particle size D.  
Interestingly the 
assignment of NODN and 
Figure 35: Value of the cumulative hypergeometric distribution function with 
constant n*Cy3 and varying levels of NODN based on a scale factor times nODN 
Figure 34: Comparison of model fit for binomial (red squares) or hypergeometric 
(black diamonds) cumulative distribution function to model uptake of Cy3-ODN. 
Even at low loadings there was no difference in the result.  
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N*ODN is not influential on the cumulative hypergeometric distribution function.  
Assigning values of NODN and N*ODN based on a simple scaling factor on nODN reveals 
this clearly in Figure 35.  This means that probability of Cy3-ODN incorporation should 
be well approximated by a binomial distribution with the probability of success equal to 
the mol fraction of Cy3-ODN used, this is confirmed in Figure 34 which shows that 
regardless of model choice the results for a test value of n*Cy3 are virtually identical, with 
only subtle differences orders of magnitude below significance. In light of these results 
we can use either distribution with confidence as the fit is not ultimately consequential, 
but will move forward with the hypergeometric distribution as the uptake of Cy3-ODN is 
best represented by the distribution “without replacement”. 
6.4.3 The bin size of characteristic distribution does not affect the model fit 
Data collected by NTA can be exported in user specified bins which represent the 
resolution of the size distribution and concentration measurement, the bin size can be set 
as low as one nanometer. When performing evaluations based on the binned data the 
resolution of the distribution could be an influencing. Consider π (D) between D=30nm 
and D=40nm at 1nm resolution, when calculating the area or volume weighting of each 
bin the small change in diameter effects a significant change in the surface area or 
volume. This growth increases the value of nODN and thus the likelihood a particle will 
surpass the loading of n*Cy3. When instead all particles from D=30nm to D=40nm are 
considered identical the total particles in the bin are given the same probability of 
containing n*Cy3 and thus as loading decreases this data input may result a sharp drop in 
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concentration as a whole bin particles being eliminated at once when the probability of 
loading n*Cy3 becomes remote for a particular value of D.  By the same token the 1nm 
resolution of π (D) 
results in more 
precise calculation 
of the cumulative 
distribution which 
might depress the 
value of n*Cy3 at 
best fit.  However 
we find the value of n*Cy3 is equivalent for both data inputs and the comparable results 
between different bin sizes are illustrated graphically in Figure 36. We also find that the 
resolution of π (D) does not impact the results comparing between hypergeometric and 
binomial distribution either, thus only the hypergeometric distribution will be used from 
here on. With the lack of meaningful impact on the result deciding what binning is most 
appropriate becomes a philosophical discussion.  One can argue that by performing NTA 
the particle diameter reported is the equivalent spherical hydrodynamic diameter, this 
sizing includes the hydration shell around the nanoparticle, and has some level of 
broadening induced by variations in track length of individual particles (although only 
“valid tracks” are used to form the size distribution).  The CLNs are by nature layered 
structures, the accessible volume changes as layers are added which is well captured with 
the 10nm binned size distribution.  Thus π (D) may be more appropriately modeled by 
using 10nm bins.  A counter argument could be made that the multilamellar structure is 
Figure 36: The influence of bin size, notice that each model fit, gray or orange is essentially 
the same for the given value of n*Cy3=100 
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not identical on every particle, and numerous TEM images [114] show a wide variation 
in the layer by layer structure where some layers may form incompletely.  Thus it is 
plausible that the 1nm bins more accurately reflect the true nature of π (D), where 
particles of virtually every size are formed by virtue of incomplete layering.  In either 
case the fit of the model to the data is equivalent. 
6.4.4 What drives the difference in value of n*Cy3 when comparing diameters vs 
concentrations? 
We note in the results that 
the model result for n*Cy3 
is lower by a factor of 
three when fit to the 
diameter ratio between 
fNTA and scNTA 
measurements as 
compared to the 
concentration ratio. The 
choice of bin width is again not influential in this fitting as shown in Figure 37.  It is not 
entirely clear what causes the difference in fitting between the two methods, where the 
expected ratio of mean diameters is consistently higher in the model than the data at the 
value of n*Cy3 which provides a good fit to the concentration ratio data.  While the value 
of n*Cy3 is within the same order of magnitude this result makes it difficult to state 
exactly what the value is. The same mass balance is closed in both cases, but clearly one 
of the models is missing something about the encapsulation in the particles. The fNTA 
Figure 37: The effect of bin size in the characteristic size distribution is clearly 
evident in the fit to the mean size ratio, with smaller bins indicating increased 
sensitivity. Data not shown below 40% as this fit is largely insensitive to n*Cy3 at 
loadings over 40% 
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measurements at loadings less than 10% are arguably the weakest data points statistically, 
as would be expected with the decreased number of tracks and the obvious bias to larger 
particle sizes.  This hypergeometric model fits the data at high loadings well with little 
regard for the value of n*Cy3 so it is possible we see an artifact of trying to a force a fit on 
the weakest section of the data, whereas the concentration approach is much more 
sensitive to changes in the high loadings.  Lastly it might be possible that all smaller 
lipoplexes form first and thus have a better chance of containing the requisite n*Cy3 
molecules of Cy3-ODN, which are depleted by the time more layers have been added, 
this would lead to an unexpectedly low ratio of mean diameters which is clear in the 
resulting n*Cy3=35 by mean ratio fit, compared to n*Cy3=100 by the concentration ratio 
fit. The total volume fraction associated with each layer grows significantly with size and 
in combination with the  
6.5 Practical applications and considerations for other fluorophores 
The practical application for determination of this value is a clear understanding of how 
many fluorescent molecules need to be concentrated in a particle to provide sufficient 
signal for accurate tracking by NTA, the value of n*Cy3 reported here is specific to the 
Cy3 fluorophore, this CLN particle system, and the particular NTA instrument 
configuration, but with this value of n*Cy3 a reasonable estimation can be made for n*Cy3 
regarding other labeling methods and probes for use in NTA. We can give further 
consideration to the meaning of n*Cy3 by examining the optical arrangement of the 
NanoSight Instrument used to measure. The equipment features a laser excitation source 
at 532nm and the fluorescent signal is collected after passing through a 565 nm long pass 
filter. Cy3 is an orange fluorescent dye with a maximum excitation at 554nm, the 
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excitation is 52% of maximum under the 532nm laser source used in these experiments. 
The emission signal is collected through the 565nm long pass filter will result in an 
additional 30% signal reduction, leaving 35% of the original signal available for tracking. 
For comparison AlexaFluor 488 (AF488), when excited with a 488 nm laser and imaged 
through a 500nm long pass filter would have 72% of its total signal available, more than 
double the Cy3. This also does not account for the inherently greater quantum yield of 
AF488, thus in a similar application one could expect that the value of n*Cy3 for AF488 
would be less than that determined in this optical arrangement for Cy3. A different dye 
which was less optimal with a chosen laser and emission filter would in turn give a higher 
values of n*Cy3.  All calculations in this section were made using Life Technologies 
Spectra Viewer.  
It should be recognized that the determination of n*Cy3 presented herein is specific to the 
Cy3 fluorophore, the CLN particle system, and the specific instrument configuration 
utilized in the experiments. The optical arrangement of the NanoSight instrument 
included a 532nm excitation source, giving 52% of maximum excitation for Cy3, and the 
data was collected through a 565nm long pass filter, leaving a total signal at 35% of the 
maximum. To consider n* for other fluorophores or particle systems the relationship 
between the optical arrangement of the measurement instrument, optimum excitation and 
emission wavelengths, and characteristic brightness of the fluorophore will alter the value 
of n* though we suspect it is within the same order of magnitude for most common 
fluorophores.  
 
 
102 
 
6.6 Comments on antibody mediated labeling of EVs 
In the course of my work at the Analytical Cytometry Shared Resource at Ohio State I 
had the opportunity to attempt to specifically label surface markers on EVs with various 
groups, none of which were distinctly unsuccessful.  Despite this I would like to take a 
moment to discuss some of the considerations that should be made with regard to 
optimization of these labeling techniques.  Labeling nanosized EVs is more difficult than 
labeling cells, the dense micron sized cells can be flooded with antibody and easily 
pelleted by a quick centrifugation to separate them from unbound antibody and/or 
excipient fluorophore. The size signature of the cell either under the microscope or on the 
forward and side scatter channels of a flow cytometer give indirect confirmation that the 
body under inspection is in fact an intact cell.  The EVs are difficult to remove from 
unbound antibody, requiring chromatography or preparative ultracentrifugation [19].  It is 
difficult if not impossible to judge the frequency of a specific biomarker within a 
heterogeneous population of EVs, making the calculation of an appropriate antibody 
concentration for complete binding difficult.  Some antibodies have equilibrium positions 
where more than 90% is free is solution when the marker of interest is saturated.  The 
minimization of free fluorophore (and thus antibody in the case of labeled primaries) in 
the solution is critical to success, thus it is useful to consider the number of EVs, the 
relative display of the marker, and in turn how many antibodies should be incubated with 
an EV sample.   Aliquot EVs so that an appropriate number for analysis (on the order of 
109 total) are contained in a small volume. Using separate samples add several different 
concentrations of antibody, to account for potentially wide variations in antibody display.  
If the frequency of a specific marker is less than 1 EV in 1000 it becomes quite unlikely 
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that labeled particles will be reliably measured by fNTA because of the timescale 
required to complete 200 valid tracks. It is possible to use secondary antibodies to 
“amplify” the signal of a single bound primary, or other biointeractive molecules such as 
biotinylated antibody and streptavidin conjugated fluorophore.  Based on the sensitivity 
to Cy3 calculated in this work, one could estimate the number of fluorophores needed for 
a different marker and in turn the demands on signal amplification if the 
frequency/display on a single EV is quite low.   
6.7 Conclusion 
In summary this chapter discusses the difficulty involved with making accurate fNTA 
measurements, particularly when the true size distribution and fluorophore content of 
nanoparticles are unknown.  Regarding the sensitivity of fNTA I am comfortable stating 
the lower limit of sensitivity for a 532nm laser/565 LP filter equipped instrument is on 
the order of 100 molecules of Cy3 per nanoparticle.  While Cy3 is not particularly well 
suited to this optical arrangement, the number of fluorophores that are seemingly required 
for accurate tracking needs to be considered for other applications including the labeling 
of EVs. The method of titration utilized in this work could be easily mimicked in a 
different model system, and values of n* for other fluorophores and optical arrangements 
documented. 
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Appendix A: NTA SOP for Analytical Cytometry Shared Resource 
NanoSight SOP at ACSR 
By: Clayton Deighan 
This document will cover all aspects of NanoSight as it pertains to sample preparation, 
data acquisition, analysis, and operation for the NS300 instrument and NTA 3.0 software.  
What is the NanoSight? 
The NanoSight is a light scattering and image processing instrument which measures 
number concentration, and size distribution for particles in suspension in the size range 
10-2000nm.  It is suitable for use with virtually any material type and buffer condition, 
given that the buffer is verified to be free of native particles.  The technique is based on 
capturing videos of Brownian motion of nanoparticles in solution, and based on this 
motion and the number of particles observed in each frame the software tracks the 
particle motion to determine the size of each particle according to the Stokes-Einstein 
equation.   
It is worth noting that the form of the Stokes-Einstein equation uses the mean squared 
displacement in two dimesions, while the particles are observed moving in a three 
dimensional space. This however is of no consequence as the two and three dimensional 
forms of the Stokes-Einstein equation are perfectly equivalent in their result.  
The instrument uses a laser diode as the illumination source, the laser passes through a 
prism which defines it shape as it enters the sample chamber. The depth of the laser is 
similar to the focal depth of the 20x objective used to observe the particles, this setup is 
the key to the technique as particles which are out of focus do not scatter any light, 
allowing those which are illuminated to be tracked frame by frame in a video and their 
size resolved based on the observed Brownian motion. The sample chamber is fitted with 
a peltier element which can control the temperature of the sample chamber between five 
degrees below ambient and 50 C, the temperature for each frame of video captured is 
recorded wether temperature control is being used or not, this combined with viscosity of 
the suspending medium leaves on the diffusion coefficient unknown, and from the 
diffusion coefficient the equivalent hydrodynamic diameter is calculated. 
The images that are appear on screen are not resolved images of the particles, that would 
be impossible with the 20x objective. Rather they are visualized as point scatterers whose 
movement can be tracked to extract the size.  
What types of samples can NanoSight measure? 
NanoSight is largely insensitive to material type, polymeric nanoparticles, liposomes, 
protein aggregates, colloidal metals, quantum dots, self assembling particles, 
microvesicles and other subcellular bodies can all be sized effectively in an NTA 
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measurement [3].  NanoSight is extremely sensitive to concentration, and requires that 
samples be diluted to an appropriate concentration before they can be effectively 
measured. The lower size limit of the measurement is determined by the scattering 
efficiency of the particles of interest, with 10nm for colloidal metals and other species of 
high refractive index, and 40nm for biologics. The lower limit of the concentration 
measurement  is 10,7 driven by the inability to complete enough tracks when the 
concentration is lower. The upper limit of concentration is 109, drive by the inability to 
properly resolve the movement of neighboring particles, and at times the propensity of 
the background subtraction feature to remove too many of the dim particles in the 
viewing vwidow, leading to erroneous counting. Methods of assessing whether a 
measurement should be accepted will be discussed later.  
How should samples be prepared? 
Sample preparation is easy, and the choice of suspending medium is largely 
inconsequential to the final result and it is the duty of the user to ensure that the medium 
is appropriate for their particles of interest. All samples should be prepared to 1 ml final 
volume for measurement. The most important part of preparing samples is moving them 
from (often) high concentration to the 108 particles/ml range necessary for measurement. 
This may require several orders of magnitude dilution and it is recommended to use 
recently calibrated pipettes, and to dilute no more than 100 times in any single step.  
For a series of measurements the user must provide enough suspending medium to dilute 
all of the samples to 1 ml volume, prime, flush, and clean the instrument after use, this 
adds up to roughly 50 ml per 10 samples. It is important to verify that the suspending 
medium is virtually particle free by running it through the instrument with the camera 
active, at which time no more than 5 particles should be visualized with the camera 
turned to its highest setting. For fluorescent nanoparticles the particle free medium 
requirement is relaxed, but it still must be verified that the suspending medium does not 
autofluoresce.  
Operational procedure (requires 10ml luer syringe for flushing/cleaning, and 1ml luer 
syringes for running samples.  
Priming the equipment and software start up 
1. Turn on the computer tower by pressing the power button in the upper corner of 
the front panel, no password is required and it will boot to the desktop. 
2. On the left hand side of the NS300 turn on the black power switch, the power 
indicator lights will come on, and the filter wheel lights should roll through one 
time (you can hear the filter wheel spin also).  
3. Turn on the NTA 3.0 software on the desktop, the screen below should open up. 
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4. In the lower left hand corner the Hardware Status panel (green box above) to tell 
you the state of the instrument, and confirm connectivity with all the components, 
FOCUS H/W, SYRINGE PUMP H/W, FILTER WHEEL H/W, and 
TEMPERATURE H/W should all show up in green text. The heater should be off 
when you start the instrument, and the temperature will be reported only when the 
module is in the instrument.  
 
5. With the system powered up you must select a top plate for the experiments you 
plan to run, there are 4 sprung screws which hold either top. The decision for 
which one to use (plastic or metal) can be dictated by your application, for aqeous 
solutions of mM salt concentration, and pH 4-7 the plastic will work fine. For 
solvents, strong acids or bases, or solutions which may have high concentrations 
of particles it is recommended to use the metal top plate. To attach the top plate to 
the laser module use the four spring loaded screws, start each screw and then hand 
tighten (NEVER USE TOOLS) each screw in a diagonal pattern until they stop. 
The same screws work with either top plate. 
 
6. With the top plate of choice attached to the laser module slide the laser into the 
machine and flip the red lever at the end of the stage guides.  
 
7. There are two hoses coming from the right side of the instrument, the leur tipped 
one will be used to introduce new samples, and flush between runs.  The other 
should be placed in the waste collection bucket, but do not allow it to sit in the 
expelled fluid in the waste collector, it should drip from above into the collection 
volume. 
 
8. To prime the instrument turn the module so that the gold connection grid is 
pointing up, the idea is air will be less likely to be trapped in the chamber, draw 
up 7-9ml of your clean medium, attach the syringe to the luer fittings and slowly 
inject the solution, you will see the sample chamber fill from top to bottom, a 
slight tilt to point the out port upwards as the chamber fills can be helpful to 
eliminate any trapped bubbles. Verify that no leaks have occurred in any of the 
hoses, connections or between the top plate and optical flat. 
 
9. When you see the solution emptying into the waste container insert the now 
primed laser block into the instrument and turn the red lever to lock it in place. 
The module light will illuminate on the front of the instrument to indicate it is in 
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place properly. When inserting the module be aware and do not damage the 
objective lens by ramming the module into it. At this point the module is primed 
and ready for sample introduction.  
Sample Analysis 
Before introducing the sample, verify the suspending medium is free from contaminating 
particles by turning on the camera with the module in place. Click the start camera (green 
box) button as indicated below, the default camera level is 7 (blue box), 7 is rarely useful, 
to check for the presence of particles in the medium turn the camera up to level 16. If 
there are a lot of particles present push on the 10ml syringe to flush more suspending 
medium through the system, if the particles cannot be eliminated then the medium is 
contaminated with particles and should not be used for NanoSight experiments. The 
acceptable level of contaminating particles can be debated based on the concentration of 
the samples to be measured, but no particles in the field of view is most desirable.  
 
When the sample chamber is sufficiently clean draw up the 1ml of diluted sample for 
measurement. One of the critical steps for quickly measuring multiple samples is good 
technique when switching from the flush syringe to the sample syringe to prevent the 
introduction of air. The luer port should never be left open to the air, when you have the 
sample drawn into the syringe remove the 10ml flush syringe and hold the port vertical 
and carefully drip two drops of the sample into the port before inserting the syringe. 
Watch carefully for a bubble when loading the syringe, if one appears, simply pull it back 
into the sample and tap it to the plunger end, keep the camera on and level at 16 during 
sample injection and wait for the particles to arrive, they should be visible by the time 
there is .4-.3ml left in the syringe.  
IF THE PARTICLES DO NOT ARRIVE 
1. Adjust the focus, roll the knob on the side of the machine top to bottom, by 
choosing the advanced tab in the software, and then the focus tab you can see the 
exact position of the objective.  
2. Remove the laser block and visually inspect for bubbles. 
3. If it seems like only a few particles arrived the sample may be too dilute, decrease 
the dilution factor.  
When the particles have arrived on screen stop the syringe injection, the particles should 
quickly stop advancing. There should be .3-.4ml remaining in the syringe when the 
particles are in view. Place the syringe in the syringe pump. The brass button on the side 
of the screw will allow the plunger holder to slide freely so that it can be positioned 
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appropriately for the size of the syringe. The plunger of the syringe sits in the slot that is 
backed by a plate with two thumbscrews, tighten the thumb screws to lock the syringe in 
place.  
To run the syringe pump go to the hardware tab, then select syringe pump, the units are 
arbitrary. With the infuse rate set to 1000, start the syringe pump until the particles move 
quickly across the screen, this is necessary to properly engage the syringe with the pump. 
Press stop, change the inject value to 30 and then click start again, the particles should 
slowly advance (5-10 sec residence time) from left to right across the screen.  
With the particles flowing use the black focus knob to set the rough focus, it is often 
useful to move between out of focus on both sides of the particles to determine the best 
position, when the particles look like nice round vibrating spheres use the fine focus to 
make any final adjustments. In polydisperse samples it is often impossible to have every 
particle perfectly in focus, blurring and diffraction rings on some of the particles will be 
present in most samples. Try to set the focus such that the smallest/dimmest particles 
visible have the clearest image. 
To set the camera level increase it to maximum 16 and work down, minimize the number 
of particles which show green false colored centers as this is indicative of saturation, 
always use the highest camera level possible. The camera level can be related to material 
type, in metals and other high refractive index materials camera levels under 10 can 
easily visualize 100nm particles. As a check one can use 100nm polystyrene spheres 
diluted 1000:1 in water, they should be visible at camera level 5-7. Biologics and other 
samples with low refractive index often require camera settings 13+ in order to be 
visualized. The screen gain does not influence the measurement and does not need to be 
adjusted. 
With the camera and focus set and the syringe pump running it is now time to create an 
SOP to take the measurement and produce results.  
In the SOP tab shown below there are several options for users to set 
Number of Captures- 5 is sufficient for almost all samples, in experiments with low 
concentration more than 5 may be used. The upper limit is 10. For samples which are 
largely monodisperse 3 captures can be sufficient to establish agreement between the run 
to run distributions. 
Length of Capture- Chosen by the number of particles visible on the screen if 30+ 
particles are visible 30 seconds is sufficient, <30 particles use 60 seconds. 
Date and time name- leave checked, appends the date and time of capture to the filename. 
Process after capture- leave checked, will prompt you to process files immediately after 
capture. 
Process settings each file- leave unchecked, process all videos under the same settings. 
Export after process- leave checked, this will prompt you for data export after the 
measurement is complete.  
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Temperature can be activated and set by choosing the boxes. It is not necessary for any 
measurement, but can be a controlled experimental parameter. 
Base File Name- Click the … button to open the file save routing. There are two 
locations appropriate for saving files Documents ->NanoVideos->Your Folder or D://-
>Your Folder. If it is your first time running samples, make a folder with your name it 
either of the two directories. Within my folder I arrange by experiment name and date. 
The location selected for the base file is where all of the associated data will be exported 
to. Name each measurement and as a good practice include the dilution factor used in the 
file name, this will prevent confusion later on. Save the filename and continue 
 
Open the Advanced menu (pictured below) and check continuous syringe pump flo, then 
choose the same syringe pump flow rate of 30. If your solution requires the use of 
different viscosity, uncheck Use Water and input the the desired value in cP. Click OK to 
close the dialogue box and save the settings. 
 
At this time the script is completely prepared, the camera and focus are set, and the 
syringe pump is running. Click create and run script to start the measurement, the 
dialogue box below will pop up, enter the relevant information and any remarks, all the 
information entered will be included on the PDF report of the results. When the 
information is complete press OK to start the script, the current step will be highlighted 
green in the Script control panel and the current repetition (for multi video runs) is 
displayed just below the script panel. After the videos have finished capture the software 
will automatically advance to processing, a dialogue box will prompt you to select the 
Detection Threshold, the detection threshold can be thought of as the signal/noise 
discrimination, when set too low many spots which are not particles will be falsely 
attempted to be tracked, and when it is set too high dim particles may be missed in the 
tracking. As the detection threshold setting is change the red and blue crosses on the 
screen will move, marking different particles, a good video will have almost all of the 
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particles marked with red crosses. To see how a setting will work throughout a video grab 
the slider just below the video viewing window and drag it forward. For many videos 
detection threshold settings of 3-5 are appropriate, if the software indicates high noise 
during processing, increase the detection threshold.  Keep a careful eye on the processing, 
if you notice that many diffraction rings or blurred areas around particles are creating 
false tracks and centres increase the detection threshold a bit more. Once again it is not 
necessary to change the screen gain as it has no influence on the results. When a 
satisfactory detection threshold is set, allow the videos to process, at the conclusion the 
export dialogue pictured below box will pop up, always select Include PDF-letter, and 
Include Experiment Summary (excel csv file). If videos for use in presentations are 
desired, choose Microsoft WMV 10 sec, each video file will be converted to a 10 sec 
wmv at much smaller size. The results files and videos will be stored in the same folder at 
the base filename directory.  
 
With the data exported the measurement and processing of one sample is complete. Turn 
the camera back on and flush the sample chamber with 3-5ml of clean diluent before 
loading the next sample. For each new sample it is only necessary to change the base 
filename and then click Run on the script panel to take the measurement.  
Clean Up 
When sample runs are complete for your time period, flush the sample cell clean with 
diluent, and then follow that with 5-7ml of DI water. Making sure the waste tube is 
removed from the collection remove the sample cell and use reverse flow on the syringe 
to remove the water from the system, this action requires slow and steady back pressure.  
When the fluid is drained remove and discard the syringe. Remove the four screws from 
the top plate and store them in the appropriate container. Wipe the optical flat and top 
plate dry with a kim wipe and replace them in the instrument for the night. Close the 
software, turn the power switch on the side of the instrument, and shut down the 
computer. To remove your data please provide a jump drive, data left on the computer 
longer than three months will be removed. 
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Appendix B: Mathematical Description of ODN loading into CLNs by Dr. Michael 
Paulaitis. 
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